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Enterococcus faecium is an opportunistic pathogen which has evolved from a commensal of 41 
the mammalian gastrointestinal tract microbiome to one of the leading causes of nosocomial 42 
infections globally. Hospital-adapted E. faecium strains, identified as members of clonal 43 
complex (CC)17, typically harbour a variety of virulence factors and antimicrobial resistance 44 
genes, including resistance to vancomycin, an essential glycopeptide antimicrobial used to treat 45 
severe Gram-positive infections. In Australia, the Australian Group on Antimicrobial 46 
Resistance (AGAR) Australian Enterococcal Sepsis Outcome Program (AESOP) identified 47 
approximately 50% of E. faecium causing blood stream infections (BSI) from 2015-2017 as 48 
vancomycin resistant. Compared to similar reports, the prevalence of vancomycin resistant E. 49 
faecium (VREfm) in Australia was higher than any nation within the European Economic Area 50 
(Highest, 43.9%, Cyprus, 2017) suggesting a serious and growing public health issue in 51 
Australia.  52 
To determine if VREfm in Australia were becoming more virulent and/or antimicrobial 53 
resistant, vancomycin non-susceptible E. faecium collected as part of a 15-year surveillance 54 
program monitoring patients admitted to high risk units at Royal Perth Hospital (RPH) were 55 
whole genome sequenced (WGS) and analysed in silico. Of the 1,372 vancomycin non-56 
susceptible E. faecium collected, 93.7% of isolates belonged to seven sequence types (STs) 57 
which were responsible for eight single strain outbreaks occurring mostly from 2010 to 2015. 58 
Except for ST173, outbreak causing STs at RPH were pandemic strains which have been 59 
previously reported internationally and across Australia. Phylogenetically, isolates were 60 
clustered according to STs with each cluster emerging from independent branches suggesting 61 
outbreak STs were distantly related. Virulence and antimicrobial profiles for each ST were 62 
shown to be unique with no increase in virulence or antimicrobial resistance observed with 63 
respect to the chronological order of outbreaks or phylogenetic order. Multiple analogous 64 
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antimicrobial resistance genes were identified indicating the independent acquisition of 65 
resistance amongst the STs and suggesting its importance in strain survival.  66 
With no increase in virulence and antimicrobial resistance observed in pandemic strains of E. 67 
faecium at RPH, subsequent investigations to determine the cause of high VREfm prevalence 68 
in Australia focused on E. faecium collected by the AGAR AESOP.  Each year, the AGAR 69 
AESOP monitors levels of antimicrobial resistance in Enterococci causing BSI throughout 70 
Australia. Since 2015, a WGS approach to surveillance was adopted by AGAR for AESOP 71 
sequencing all E. faecium referred by participating laboratories. Using bioinformatics, E. 72 
faecium from 2015-2017 were shown to form three main phylogenetic clusters consisting of (i) 73 
predominantly vancomycin susceptible isolates which did not harbour any van operons, (ii) 74 
predominantly VREfm isolates harbouring the vanA operon and (iii) predominantly VREfm 75 
isolates harbouring the vanB operon. Further investigations of the two VREfm dominant 76 
clusters responsible for the high prevalence of VREfm in Australia revealed isolates located on 77 
distal phylogenetic branches showed increased prevalence of the respective vanA or vanB 78 
operons compared to basal isolates. The findings suggest the development of an affinity 79 
between certain E. faecium strains with a particular van genotype. As a result, the majority of 80 
ST1421 and ST1424 isolates located on the distal branches of the vanA dominant cluster, 81 
harboured the vanA operon while the majority of ST555 and ST796 isolates located on the 82 
distal branches of the vanB dominant cluster, harboured the vanB operon. Additionally, in 83 
clusters with increased van operon prevalence, an increased 30-day all-cause patient mortality 84 
and increased number of isolates was observed.  85 
The vanA and vanB operons conferring vancomycin resistance identified in AGAR AESOP 86 
isolates are located on mobile genetic elements which can be transferred between bacteria. To 87 
investigate the transmission of van operons, additional insertion sequences (ISs) identified 88 
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between van genes were used to type each van operon. Five IS elements were identified within 89 
vanA operons while three IS elements were identified within vanB operons. In combination 90 
with van genes, eight vanA operon types and five vanB operon types were identified in the 91 
2015-2017 AGAR AESOP collection of E. faecium isolates. The majority of IS elements were 92 
identified in intergenic regions between the regulatory, essential and accessory gene groups of 93 
the vanA and vanB operon. Phylogenetic analysis showed vanA and vanB operons clustered 94 
according to isolate STs suggesting van operons were mostly inherited via vertical 95 
transmission. The operon from vanA dominant strains ST1421 and ST1424, and the operon 96 
from vanB dominant strains ST555 and ST796 were distantly related to international reference 97 
operons suggesting that the majority of locally distributed vanA and vanB operons in Australia 98 
have evolved independently rather than from international VREfm. 99 
In conclusion, pandemic strains of VREfm in Australia showed no indication of increasing 100 
virulence or antimicrobial resistance over time. Analysis of E. faecium causing BSI in Australia 101 
showed three phylogenetic clusters, of which, two were dominant for the vanA and vanB 102 
operon respectively and were responsible for the high VREfm prevalence observed in 103 
Australia. Both VREfm dominant clusters showed increasing prevalence of the respective 104 
vanA or vanB operons in isolates located toward the distal branches of the phylogenetic tree 105 
suggesting a strain-van operon affinity. Typing of the vanA and vanB operons suggests van 106 
operons identified in Australia were locally distributed and are distantly related to van operons 107 
from international VREfm.  108 
  109 
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1.2 ABSTRACT 391 
Enterococcus faecium are robust opportunistic pathogens that are most commonly found as 392 
commensals of the human and animal gut but can also survive in the environment. Since the 393 
introduction and use of antimicrobials, E. faecium have been found to rapidly acquire resistance 394 
genes which when expressed can effectively circumvent the effects of most antimicrobials. The 395 
rapid acquisition of multiple antimicrobial resistances has led to the adaptation of specific E. 396 
faecium clones in the hospital environment collectively known as clonal complex (CC)17. 397 
CC17 E. faecium are responsible for a significant portion of hospital-associated infections, 398 
which can cause severe morbidity and mortality. Here, we review the history of E. faecium 399 
from commensal to a significant hospital-associated pathogen, its robust phenotypic 400 
characteristics, commonly used laboratory typing schemes and antimicrobial resistances with 401 
a focus on vancomycin and its associated mechanism of resistance. Finally, we review the 402 
global epidemiology of vancomycin resistant E. faecium and potential solutions to problems 403 
faced in public health.  404 
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2.1 AUTHOR CONTRIBUTIONS 424 
TL designed the study, analysed and interpreted the data, and drafted the manuscript. GWC 425 
designed the study and critically revised the manuscript. SP guided the analysis and 426 
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2.2 ABSTRACT 428 
The first outbreak of vancomycin-resistant Enterococcus faecium (VREfm) in Western 429 
Australia was recorded in 2001. A state-wide infection control effort that oversaw patient 430 
screening and transfers successfully terminated the outbreak within six months; however, the 431 
outbreak re-emerged two years later. Over the two outbreaks, the vanB-positive multilocus 432 
sequence type (ST) 173 E. faecium strain was isolated from 201 patients. Our objective was to 433 
identify differences in genetic traits leading to successful transmission of ST173 VREfm 434 
compared with non-ST173 VREfm isolated during the same period. We also aimed to describe 435 
the changes observed in the ST173 VREfm genome collected during the two outbreaks. 436 
Virulence factors ecbA, fss3, psaA and scm identified in the non-ST173 isolates were largely 437 
absent in the ST173 isolates. The esp gene was not identified beyond 45% coverage for any 438 
isolate in this study. In terms of resistance genes, tet(U) was identified in 94.7% of ST173 439 
VREfm isolated in the first outbreak but was largely absent in ST173 VREfm isolated in the 440 
second outbreak and in non-ST173 VREfm. Seven ST173 VREfm isolates (Clade A) carried 441 
dfrG but not tet(M) resistance genes. The average genome size of ST173 VREfm isolated in 442 
the first outbreak was significantly larger than the genome size of ST173 VREfm isolated in 443 
the second outbreak. The reduced number of virulence factors in ST173 isolates may explain 444 
the low infection and high colonization rates observed during the outbreak. In addition, isolates 445 
with larger genomes were found to be associated with outbreaks. 446 
  447 
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3.1 AUTHOR CONTRIBUTIONS 467 
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3.2 ABSTRACT 472 
Objectives 473 
The objective of the study was to describe the molecular characteristics and relationship 474 
between vancomycin non-susceptible Enterococcus faecium outbreak strains and to determine 475 
if outbreak strains were becoming more virulent and antimicrobial resistant over time.  476 
Methods  477 
Vancomycin non-susceptible Enterococcus faecium from patients admitted to high-risk units 478 
from 2001 to 2015 were retrospectively analysed using a whole genome sequencing and 479 
bioinformatics approach. 480 
Results 481 
Eight single-strain outbreaks belonging to seven sequence types (STs) were identified. 482 
Outbreak STs accounted for 93.7% of vancomycin non-susceptible E. faecium isolates 483 
collected. Except for ST173, outbreak STs identified at RPH were pandemic strains. Isolates 484 
from each ST formed independently branched phylogenetic clusters with each harbouring 485 
unique virulence and antimicrobial resistance profiles. Depending on the ST, different genes 486 
conferring resistance to similar antimicrobial classes were identified. Except for ST80 which 487 
harboured the vanA type operon, all outbreak strains harboured the vanB operon conferring 488 
only vancomycin resistance. 489 
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Conclusion  490 
Outbreak strains isolated over 15-years showed unique virulome and resistome profiles with 491 
no indication of increasing virulence or antimicrobial resistance. Strains were distantly related 492 
and the acquisition of analogous resistance genes suggest the independent evolution of 493 
outbreak strains which were most likely introduced to the facility.  494 
  495 
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3.3 INTRODUCTION 496 
Enterococcus faecium is a Gram-positive bacterium most commonly identified as part of the 497 
mammalian gastrointestinal microbiome. Previously considered a commensal, the global 498 
emergence of a hospital-adapted subpopulation, known as clonal cluster (CC)17, has been 499 
identified as the clade responsible for the majority of healthcare-associated E. faecium 500 
infections (1).  501 
Identified by multilocus sequence typing, CC17 are a group of E. faecium strains related by 502 
single or double locus variants to the predicted founder, sequence type (ST)17 (1). 503 
Phenotypically, CC17 E. faecium are often resistant to multiple antimicrobial classes and 504 
harbor a variety of virulence determinants (2). One of the most concerning characteristics of E. 505 
faecium is their ability to acquire glycopeptide resistance; in particular the glycopeptide 506 
antimicrobial vancomycin which is listed as an essential medicine for infections involving 507 
Gram-positive bacterium (3). Vancomycin resistance in E. faecium is conferred by a series of 508 
regulatory, functional and accessory genes forming the van operon (4). Currently, the vanA, 509 
vanB and vanM genotypes have greater clinical importance as they confer intermediate to high 510 
levels of resistance and are located on mobile genetic elements that can be horizontally 511 
transferred to other bacteria (2). 512 
In Australia, vancomycin resistance in E. faecium is typically conferred by the acquisition of 513 
the vanA or vanB operon. Initially reported in 1995 (5), vancomycin resistant E. faecium 514 
(VREfm) is now endemic in many Australian hospitals with outbreaks reported regularly (6-515 
8).  516 
In this study, we retrospectively analyse a fifteen-year collection of vancomycin non-517 
susceptible E. faecium from Royal Perth Hospital (RPH), a 450-bed teaching hospital located 518 
in Perth, Western Australia (9). Prior to 2001, only sporadic cases of vancomycin non-519 
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susceptible E. faecium harbouring the vanA genotype were identified during the routine 520 
surveillance of patient’s admitted to the hospital’s high-risk wards. In 2001, a single strain 521 
outbreak of a vancomycin non-susceptible E. faecium harbouring the vanB type operon was 522 
occured (10). A large-scale effort to prevent vancomycin non-susceptible E. faecium from 523 
becoming endemic in the hospital led to the termination of the outbreak shortly after. However, 524 
since 2001, surveillance at the facility has detected multiple single strain outbreaks of 525 
vancomycin non-susceptible E. faecium with unique STs. 526 
In this study, we aim to investigate the molecular characteristics and relationship between the 527 
major vancomycin non-susceptible E. faecium strains isolated at RPH and to determine if 528 
vancomycin non-susceptible E. faecium strains are becoming more virulent and antimicrobial 529 
resistant. To achieve this, we retrospectively analysed isolates collected during a 15-year 530 
surveillance period using next-generation whole genome sequencing (WGS) and 531 
bioinformatics. 532 
  533 
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3.4 METHODS 534 
Sampling. From 2001 to 2015, surveillance rectal swabs were collected from all patients on 535 
admission to the high-risk wards at RPH. E. faecium recovered from overnight cultures were 536 
tested for vancomycin susceptibility using Etest® (bioMérieux, France). Minimum inhibitory 537 
concentrations (MICs) were classified according to CLSI guidelines with isolates exhibiting ≥ 538 
16 µg/ml vancomycin MICs identified as vancomycin non-susceptible (11). Vancomycin non-539 
susceptible E. faecium isolates were characterised using the multilocus sequence typing scheme 540 
described by Holman et al. (12). A single-strain outbreak was defined by the accumulation of 541 
more than 20 isolates with the same ST within a twelve-month period. Except for ST173 542 
isolates, which were previously whole genome sequenced, 20-25 isolates from each outbreak 543 
were randomly selected for WGS. 544 
Whole Genome Sequencing. Isolates were recovered from -80°C broth and subcultured twice 545 
on sheep blood agar. DNA extraction was performed on secondary cultures using the 546 
MagMaxTM DNA extraction kit (Thermo Fisher Scientific, United States) on the MagMAXTM 547 
express-96 deep well magnetic particle processor (Thermo Fisher Scientific, United States) 548 
according to the described protocol. DNA libraries for next-generation sequencing were 549 
prepared using the Illumina® Nextera® XT DNA Library Prep Kit (Illumina, United States) as 550 
per manufacturer’s protocol. WGS was performed using the Illumina® NextSeqTM 500 platform 551 
based on the 150bp chemistry.  552 
Bioinformatics. DNA sequences were quality checked for a minimum of 40x depth and 75% 553 
sequence identity with the reference genome, AUS0004 (Accession: PRJNA86649). Raw 554 
sequencing reads were cleaned using Trimmomatic V0.38 (13) before assembly by SPAdes 555 
(14).Gene identification and annotation was performed using Prokka (15) with the resulting 556 
files used as input for pan genome analysis using roary V3.12.0 (16). The multilocus sequence 557 
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type (MLST) for each isolate was determined using the scheme described by Holman et al. 558 
(12) with sequence definitions hosted on the BIGsdb database 559 
(https://pubmlst.org/software/database/bigsdb/). Isolates with one or more ambiguous MLST 560 
alleles were categorized as undefined and excluded from the study. CCs were determined based 561 
upon single or double locus variants of E. faecium STs defined in BIGSdb. The Virulence and 562 
resistance genes were identified using Abricate V0.8.7 in tandem with VFDB (17) 563 
(21/01/2019) and the ResFinder (18) (21/01/2019) databases for virulence factors and 564 
resistance genes respectively. Except for esp, identification of resistance genes and virulence 565 
factors were indicated by a minimum sequence homology of 95% to respective database 566 
entries. Due to the limitations of the sequencing methodology in resolving repeat regions, the 567 
esp virulence factor was deemed present at 40% sequence homology (19). Functional van 568 
operons were determined by the presence of regulation genes (vanR and vanS) and essential 569 
genes (vanH, vanA/vanB, vanX) within the respective vanA or vanB operon. Single nucleotide 570 
polymorphisms (SNPs) were identified using Snippy V4.1.0 (20) and the removal of 571 
recombinant DNA segments was performed on SNP alignments using ClonalFrameML V1.11 572 
(21). Maximum likelihood phylogenetic trees based on the SNP alignments were constructed 573 
in RAxML V8.2.11 (22) with bootstrap values set at 1000 using the general time-reversible-574 
CAT model. The iTOL V3 web service was used to visualize the phylogenetic tree with 575 
available metadata. Bacterial phages were identified using the PHASTER web service 576 
(http://phaster.ca/) (23) with only intact prophages (score >90) reported. 577 
Statistical analysis. Isolates collected were visualised using the bubble plot function in the 578 
ggplot2 library (24) in R (25). All sequenced isolates were subjected to principal component 579 
analysis (PCA) of binomial variables in Python to determine the association of gene content 580 
based on gene presence and absence output by roary (26). 581 
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Raw sequence files were uploaded to the National Center for Biotechnology Information 582 
Sequence Read Archive (NCBI-SRA) under BioProject accession numbers PRJNA575940 and 583 
PRJNA524213.  584 
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3.5 RESULTS 585 
From the 1,372 vancomycin non-susceptible E. faecium isolated from non-duplicate patient 586 
samples collected from 2001 to 2015, 1,125 isolates belonged to 15 known STs, of which 14 587 
were members of CC17. Over the 15-year period, seven STs were identified in eight single 588 
strain outbreaks with ST173 responsible for two successive but non-contiguous outbreaks. 589 
Vancomycin non-susceptible E. faecium outbreaks occurred in 2001, 2004, 2010, 2011, 2013 590 
(2 outbreaks), 2014 and 2015 (Figure 3.1). Outbreak STs ST173, ST203, ST18, ST78, ST341, 591 
ST555 and ST80, all members of CC17, accounted for 93.7% of isolates collected. Four 592 
hundred and fifty-one outbreak isolates were selected for WGS. Thirty isolate sequences were 593 
below the WGS quality threshold and therefore were excluded from the study. 594 




Figure 3.1 Bubble plot visualizing the sequence types and number of isolates collected each year. 597 
Shaded area indicates outbreak years.  598 
  599 
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The average genome size of isolates was 2,928,766 bp with an interquartile range of 2,879,018 600 
and 2,986,874 bp. Using bioinformatics analysis, 6,062 genes were identified with 1,890 core 601 
genes present in more than 99% of isolates. Using principal components analysis, principal 602 
components one and two explained 16.2% and 0.6% of the variance observed in the total gene 603 
content of isolates respectively. Plotted on a 2D-axis, principle components one and two 604 
grouped ST78, ST203, ST341 and ST555 while ST173, ST18 and ST80 were independent 605 




Figure 3.2. Visualization of the top two principal components derived from the total gene content plotted 608 
in two dimensions. Sequence types are colour coded as per the legend and ellipse represent 95% 609 
confidence.  610 
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The maximum likelihood SNP inferred phylogeny of sequenced outbreak isolates showed a 611 
strict clustering of isolates by STs (Figure 3.3). Typically, each ST emerged from independent 612 
phylogenetic branches. ST78 and ST203 however shared the same primary phylogenetic 613 
branch with further branching observed. Chronologically, ST173 isolates were collected from 614 
the first vancomycin non-susceptible E. faecium outbreak and were the most distant 615 
phylogenetically. No further trend was observed between the phylogenetic order and the 616 
chronological order for the remaining STs. The distribution of van genotype amongst isolates 617 
was strictly associated to phylogeny with the vanA operon only identified in ST80 isolates.   618 




Figure 3.3. A mid-point rooted maximum likelihood phylogenetic tree of outbreak vancomycin resistant 621 
Enterococcus faecium isolates inferred from single nucleotide polymorphism mutations. The van 622 
operon type is indicated by the colour of the arc according to the legend. Sequence types for each branch 623 
are indicated outside the arc. 624 
  625 
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Resistome. Overall 19 antimicrobial resistance genes were identified from all sequenced 626 
isolates (Table 3.1), of which, the AAC(6’) and msr(C) genes were ubiquitous amongst all STs. 627 
The average number of resistance genes identified in the outbreak STs was 10.2. ST173, 628 
ST203, ST18, ST78, ST341, ST555 and ST80 isolates harboured an average of 10.7, 10.0, 10.3, 629 
7.7, 9.3, 12.6 and 7.9 resistance genes per isolate respectively. Approximately, 70% of ST555 630 
sequences harboured 13 resistance genes, the highest number of resistance genes amongst all 631 
sequenced isolates.  632 
Antimicrobial resistance gene profiles were mostly identical for isolates within an ST with 633 
90.2% of genes identified present or absent in >90% of isolates. For antimicrobial resistances 634 
conferred by analogous genes such as tetracycline resistance genes, tet(L), tet(M) and tet(S), 635 
no particular gene was dominant across all STs. For example, ST80 isolates only harboured 636 
tet(S), ST203 and ST555 isolates only harboured tet(M), and ST173 and ST78 harboured tet(L) 637 
and tet(M) genes.  638 
Vancomycin resistance for ST173, ST203, ST18, ST78, ST555 and ST341 isolates were 639 
encoded by the vanB operon while ST80 isolates were encoded by the vanA operon. All isolates 640 
harboured only one van operon. In 76.5% of ST78 isolates the vanB operon did not possess the 641 
regulatory vanRB and vanSB genes. Consequently, the isolates had an MIC below the CLSI 642 
vancomycin resistant breakpoint.643 
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Table 3.1 Summary of antimicrobial resistance genes identified in outbreak sequence types in percentages. 644 
ST 














aac(6') ant(6)-Ia aph(3')-IIIa tet(L) tet(M) tet(S) dfrF dfrG eat(A) lsa(E) erm(B) erm(T) vanA vanB lnu(B) msr(C) sat4 cat-TC 
ST173 89.1 100.0 97.1 97.1 97.7 95.4 0.0 0.0 4.6 98.3 0.0 96.0 3.4 0.0 97.7 0.0 99.4 96.0 0.0 203 (86.2) 
ST203 64.3 100.0 62.5 100.0 0.0 64.3 0.0 96.4 0.0 100.0 50.0 100.0 0.0 0.0 100.0 58.9 100.0 0.0 0.0 89 (62.9) 
ST18 26.3 100.0 100.0 0.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 100.0 100.0 0.0 100.0 0.0 100.0 0.0 100.0 35 (57.1) 
ST78 0.0 100.0 23.5 0.0 100.0 76.5 0.0 76.5 23.5 100.0 0.0 23.5 100.0 0.0 23.5 0.0 100.0 0.0 23.5 57 (57.9) 
ST341 97.0 100.0 97.0 97.0 0.0 0.0 0.0 0.0 100.0 0.0 84.8 57.6 0.0 0.0 100.0 97.0 100.0 0.0 0.0 61 (54.1) 
ST555 91.7 100.0 98.3 98.3 0.0 98.3 0.0 91.7 100.0 100.0 81.7 100.0 0.0 0.0 100.0 98.3 100.0 0.0 0.0 565 (10.6) 
ST80 6.8 100.0 4.5 93.2 0.0 0.0 97.7 0.0 0.0 100.0 0.0 97.7 0.0 97.7 0.0 0.0 100.0 93.2 0.0 48 (91.7) 
1 lincosamide, streptogramin A and pleuromutilins (LSaP) 645 
2 macrolides, lincosamides and streptogramin B (MLSb)  646 
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Virulome. Nine virulence factors were identified from all sequenced isolates (Table 3.2). The 647 
acm (99.1%), bsh (100%), clpP (99.8%) and bopD (100%) virulence genes were dominant in 648 
all STs. On average each isolate harboured 6.0 virulence factors. ST203 isolates harboured all 649 
virulence factors, except for 5.4% of isolates which did not possess the sgrA gene. The ecbA 650 
surface adhesin gene was only identified in ST203 isolates. The esp gene was present in all 651 
ST203, ST78, ST341, ST555 and ST80 sequenced isolates. Apart from ST555 and ST80, the 652 
virulence profiles for each ST was unique for that ST. Similar to the antimicrobial resistance 653 
genes, most isolates within an ST harboured the same virulence factors with 96.4% of genes 654 
present or absent in > 90% of isolates.  655 
  656 
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Table 3.2 Summary of virulence genes identified in outbreak sequence types in percentages.  657 
 Surface Adhesins  Bile Salt Hydrolase Proteolysis Biofilm 
ST acm sgrA ecbA fss3 psaA esp bsh clpP bopD 
ST173 98.3 98.9 0.0 0.6 0.6 0.6 100.0 99.4 100.0 
ST203 100.0 94.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
ST18 100.0 100.0 0.0 0.0 0.0 0.0 100.0 100.0 100.0 
ST78 100.0 100.0 0.0 23.5 100.0 100.0 100.0 100.0 100.0 
ST341 100.0 0.0 0.0 100.0 100.0 100.0 100.0 100.0 100.0 
ST555 100.0 91.7 0.0 96.7 100.0 100.0 100.0 100.0 100.0 
ST80 100.0 88.6 0.0 100.0 100.0 100.0 100.0 100.0 100.0 
  658 
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Phage. Five intact prophages were detected (Table 3.3); four belonged to the Siphoviridae 659 
family and one belonged to the Podoviridae family of viruses. Of the four Siphovidae viruses, 660 
IME_Efm5 and phiFL1A were enterococcal phages, and PSA and B025 were listerial phages. 661 
The phage identified from the Podoviridae family was identified as Bacillus phage phBC6A52.  662 
The E. faecium prophage IME_Efm5 was identified in 98.3% of ST173 and 39.3% of ST203 663 
isolates. The listeria prophage PSA was identified across most STs in 28.6%, 94.7%, 17.6%, 664 
3.0%, 80.0% and 68.2% of ST203, ST18, ST78, ST341, ST555 and ST80 isolates respectively.  665 
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ST173 98.3 0.0 2.9 0.0 0.0 
ST203 39.3 85.7 28.6 0.0 57.1 
ST18 0.0 0.0 94.7 0.0 0.0 
ST78 0.0 0.0 17.6 0.0 0.0 
ST341 0.0 0.0 3.0 0.0 0.0 
ST555 0.0 88.3 80.0 0.0 0.0 




3.6 DISCUSSION 668 
Infection control surveillance of vancomycin non-susceptible E. faecium carriage in patients 669 
admitted to the high-risk wards at RPH identified an increasing occurrence of single strain 670 
outbreaks over the fifteen-year study period. The first two outbreaks, occurring in 2001 and 671 
2004, were due to ST173, a ST that not been reported outside Western Australia. In contrast, 672 
the other six STs responsible for single strain outbreaks occurring between 2010 and 2015 have 673 
been reported in nation-wide surveillance studies in several geographical regions of Australia 674 
(6, 27).  675 
Most sequenced outbreak STs contained genes conferring resistance towards aminoglycosides, 676 
tetracyclines, trimethoprim, lincosamides, streptogramins A, streptogramins B, pleuromutilins 677 
and macrolides suggesting harbouring resistance to these classes of antimicrobials may be 678 
important for strain survival in the hospital environment. Additionally, the presence of 679 
analogous resistance genes suggests the independent acquisition of genetic material. The 680 
antimicrobial resistance profiles of each ST showed that dominant outbreak strains were not 681 
becoming more antimicrobial resistant over time. 682 
Virulence factors acm, bsh, clpP and bopD were present in the majority of isolates. The ecbA 683 
surface adhesin however was unique to ST203. Despite the high prevalence of putative 684 
virulence factors identified in sequenced outbreak isolates, most virulence factors were 685 
associated with adhesion and survival rather than pathogenicity. Major virulence factors 686 
previously identified in E. faecium, such as asa1, gelE and hyl encoding aggregation substance, 687 
gelatinase and hyaluronidase (28) were not identified. The virulence profile identified in 688 




When comparing each outbreak STs to each other, ST173 differed the most in terms of total 691 
gene content (based on PCA) and most distantly related (based on SNP phylogeny). 692 
Accounting for the second highest number of isolates, the two ST173 outbreaks were resolved 693 
within a year, after which VREfm at the hospital decreased significantly. The short duration of 694 
the two outbreaks could be due to the IME-EFm5 phage identified in the majority of ST173 695 
isolates. IME-EFm5 have been previously reported to show very specific host range and 696 
possess LysEFm5, a putative lysin protein (29). However, LysEFm5 was not identified in IME-697 
EFm5 from ST173-RPH isolates. After the second outbreak ST173 has not been identified 698 
again. 699 
Subsequent to the ST173 outbreaks, a vanB ST203 outbreak occurred at RPH in 2010. In the 700 
same year, vanB ST203 was reported on the eastern seaboard of Australia at Austin Health in 701 
Victoria (7). Despite the introduction of a range of infection control practices at Austin Health, 702 
which resulted in a marked reduction in methicillin resistant Staphylococcus aureus 703 
bacteraemia episodes, ST203 VREfm caused a large and sustained outbreak. Compared to 704 
vanB ST203 at RPH and Austin Health, international reports of ST203 isolates mostly 705 
harboured the vanA type operon (30, 31). At RPH most of the vanB ST203 isolates harboured 706 
all identified virulence factors including ecbA which was only identified in ST203. ST203 has 707 
previously been identified in Norway. Like the RPH ST173, the Norway ST203 has showed a 708 
significantly higher number of virulence factors compared to non-ST203 isolates (32).  709 
ST18 was first isolated at RPH in 2010 and was responsible for an outbreak the following year. 710 
In terms of resistance, the chloramphenicol resistance determinant conferred by cat-TC was 711 
frequently identified in to ST18 isolates only. Globally, ST18 was first identified in 2005 and 712 
harboured either vanA or vanB operons (33-35).  713 
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Although ST78 vancomycin non-susceptible E. faecium was initially identified at RPH in 2001, 714 
an outbreak of ST78 did not occur until 2011. Two distinct phylogenetic branches were 715 
identified for ST78 during the outbreak. The absence and presence of eight different genes 716 
within the resistome and virulome between the two branches of isolates was observed. Further 717 
investigation of the assembled genomes (not shown) showed the eight genes were present in 718 
different segments of the genome suggesting each gene was independently acquired. This 719 
suggests the two groups of ST78 are more likely to have evolved independently.  720 
ST341 was first isolated at RPH in 2010 and was responsible for an outbreak in 2013. ST341 721 
was the only outbreak strain which did not harbour any tetracycline resistance determinants 722 
and the sgrA virulence factor. Genetically, based on PCA, ST341 was similar to ST203 and 723 
ST78 but not closely related to either STs phylogenetically. A recent study involving ST341 724 
and ST555, identified significant alcohol tolerance but did not establish causation (36).  725 
The longest and largest outbreak in terms of number of isolates at RPH was caused by ST555. 726 
A 2013 report identified ST203 and ST555 as the two predominant strains causing VREfm 727 
sepsis in Australia (37). The overlapping 95% confidence ellipse of ST203 and ST555 in the 728 
PCA suggests the two STs share similar genetic features compared to other outbreak STs. A 729 
recent study has identified ST555 as the ancestral progenitor of a worldwide epidemic clone, 730 
ST796 which emerged in 2012 (37-39). 731 
ST80 was first isolated at RPH in 2012 and was responsible for an outbreak in 2015. Although 732 
all ST80 isolates harboured the vanA operon in this study, elsewhere ST80 isolates have been 733 
reported to harbour the vanB operon (40). 734 
Our study had several limitations. Firstly, as with all retrospective studies, we were not able to 735 
account for all confounding factors. Additionally, only isolates from the hospitals high-risk 736 
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units were included in the study. Furthermore, sequenced isolates were only a subset of the 737 
outbreak isolates collected and assumed to be representative of the outbreak strain.  738 
In conclusion, although changes were observed in the virulome and resistome of vancomycin 739 
non-susceptible E. faecium outbreak strains ST173, ST18, ST203, ST 341, ST80, ST78 and 740 
ST555 isolated at RPH over a 15-year period, no indication of increasing virulence or 741 
antimicrobial resistance was observed. The outbreak strains identified were phylogenetically 742 
distant suggesting each ST evolved independently. The presence of multiple analogous 743 
resistance genes amongst outbreak STs supports the independent evolution and suggest the 744 
importance of antimicrobial resistance in strain survival.  745 
  746 
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4.2 ABSTRACT 893 
Over the last three decades, hospital adapted clonal complex (CC) 17 strains of Enterococcus 894 
faecium have acquired and exchanged antimicrobial resistance genes leading to the widespread 895 
resistance to clinically important antimicrobials globally. In Australia, a high prevalence of 896 
vancomycin resistance has been reported in E. faecium in the last decade. In this study, we 897 
determined the phylogenetic relationship and genetic characteristics of E. faecium collected 898 
from hospitalized patients with blood stream infections throughout Australia from 2015 to 2017 899 
using high throughput molecular techniques.  900 
Using single nucleotide polymorphism based phylogenetic inference, three distinct clusters of 901 
isolates were observed.  902 
One cluster harboured mostly non-CC17 isolates while two clusters were dominant for the 903 
vanA and vanB operons. The gradual increase in dominance of the respective van operon was 904 
observed in both the vanA and vanB dominant clusters suggesting a strain-van operon 905 
affinity. The high prevalence of the van operon within isolates of a particular sub-cluster was 906 
linked to an increased number of isolates and 30-day all-cause mortality. Different dominant 907 
sub-clusters were observed in each region of Australia. 908 
Findings from this study can be used to put future surveillance data into a broader perspective 909 
including the detection of novel E. faecium strains in Australia as well as the dissemination and 910 
evolution of each strain.  911 
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4.3 INTRODUCTION 912 
Enterococcus faecium is a species of Gram-positive bacterium most commonly found as a 913 
commensal of the mammalian gut microbiome. However not all E. faecium strains exists solely 914 
as commensals, with some harbouring the ability to cause invasive infections (1). In 915 
hospitalized patients, the vast majority (>90%) of enterococci identified are either E. faecalis 916 
or E. faecium (2). Although E. faecalis are more often responsible for infections, it is the 917 
nosocomial E. faecium infections that are typically resistant to multiple antimicrobial classes. 918 
Infections resulting from antimicrobial resistant E. faecium have limited therapeutic options 919 
and are challenging to treat clinically (3).  920 
The E. faecium responsible for the majority of hospital acquired infections consists of various 921 
sequence types (STs) related to clonal complex (CC) 17 (4). The acquisition of vancomycin 922 
resistance genes in CC17 E. faecium is of serious concern as vancomycin is also used for the 923 
treatment of other Gram-positive bacterial infections including methicillin-resistant 924 
Staphylococcus aureus (5). Of the known van genotypes conferring vancomycin resistance, the 925 
vanA, vanB and vanM genotypes have the greatest clinical significance as they confer 926 
intermediate to high levels of resistance and reside on genetic elements that can not only be 927 
transferred within enterococci but to other bacteria (6-8). 928 
To ensure antimicrobial agents provide the best treatment outcomes with minimal risk of 929 
adverse effects, including the development of antimicrobial resistance (9), robust surveillance 930 
of antimicrobial resistant bacteria is required.  In Australia, the Australian Group on 931 
Antimicrobial Resistance’s (AGAR) Australian Enterococcal Sepsis Outcome Program 932 
(AESOP) closely monitors enterococcal isolates from episodes of blood stream infection (BSI) 933 
across the country. In the 2015, 2016 and 2017 AESOPs the percentage of E. faecium BSIs that 934 
were vancomycin resistant was 46.5%, 50.1% and 47.0%, respectively (10-12). Compared to 935 
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the population-weighted mean of 8.3%, 11.8% and 14.2% for nations within the European 936 
Economic Area over the same time period (13-15), the high prevalence of vancomycin-resistant 937 
E. faecium (VREFm) BSIs in Australia represents a serious public health concern (16).  938 
To understand the high prevalence of nosocomial VREfm causing enterococcal bacteraemia in 939 
Australia, a whole genome sequencing (WGS) bioinformatics approach was used to determine 940 
the relationship and characteristics of E. faecium isolates from the 2015, 2016 and 2017 941 
AESOPs. 942 
4.4 MATERIALS AND METHODS 943 
Isolates were sourced from the 2015, 2016 and 2017 AGAR AESOPs. As part of the AESOPs, 944 
enterococcal isolates were referred to a central reference laboratory where WGS was performed 945 
on all E. faecium isolates. Libraries for WGS were prepared with the Illumina® Nextera® XT 946 
DNA Library Prep Kit (Illumina, United States) according to the prescribed protocol. 947 
Sequencing was performed on either the MiseqTM or NextSeqTM platform using the 600-cycle 948 
Reagent Kit v3 and the 300-cycle mid output Reagent Kits v2 respectively. As part of quality 949 
control, sequence data of isolates yielding less than 40x depth and 50% coverage to the 950 
reference chromosome of E. faecium Aus0004 (GenBank CP003351), were excluded from the 951 
study.  952 
For each isolate, raw sequencing reads were cleaned using Trimmomatic V0.38 (17) before 953 
being assembled by SPAdes (18) followed by gene identification and annotation by Prokka 954 
V1.13 (19). Pan genome analysis was performed using Roary V3.12.0 (20) on Prokka 955 
generated files. Virulence and resistance genes were identified using ABRicate V0.8.7 in 956 
tandem with VFDB (21/01/2019) (21) and the ResFinder (21/01/2019) (22) databases 957 
respectively. Positive identification of resistance genes and virulence factors were indicated by 958 
a minimum sequence homology of 85% to respective database entries. Analysis of the esp 959 
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virulence factor was excluded from this study due to the limitations of the sequencing 960 
methodology in resolving repeat regions within the esp gene (23). Functional van operons were 961 
determined by the presence of regulation genes (vanR and vanS) and essential genes (vanH, 962 
vanA/vanB, vanX) within the respective vanA or vanB operon. The ST for each isolate was 963 
determined using the scheme described by Homan et al. (24) with sequence definitions hosted 964 
on the BIGSdb (https://pubmlst.org/software/database/bigsdb/) database (25). Isolates with one 965 
or more ambiguous MLST alleles were categorized as undefined and excluded from the study. 966 
The BURST diagram describing the relationship of STs was constructed using eBURST V3 967 
(26). Single nucleotide polymorphisms (SNPs) were identified using Snippy V4.1.0 (27). 968 
Removal of recombinant DNA segments was performed on SNP alignments using 969 
ClonalFrameML V1.11 (28). Phylogenetic trees were constructed using the maximum 970 
likelihood method based on the SNP alignments in RAxML V8.2.11 (29) with the GTRCAT 971 
model and bootstrap values set at 1000.  The main phylogenetic tree was constructed using all 972 
isolates with the root placed the most distantly related isolate. The most distantly related isolate 973 
was determined by SNP inferred phylogeny of isolates with a distantly related reference from 974 
the E. durans species (Accession: CP012366). To enhance SNP resolution in major branches 975 
of the main phylogenetic tree, SNP analysis was repeated on subsets of isolates labelled as 976 
clusters. Individual cluster phylogeny was analysed using the previously described method 977 
with the root placed at the most distantly related isolate determined by the main phylogenetic 978 
tree. Further sub-clustering was performed based on distinct branches of each phylogenetic 979 
tree. The iTOL V3 (30) web service was used to visualize the phylogenetic tree along with the 980 
metadata.  981 
All statistical analysis was performed with the statistical package R (31). The association 982 
between clusters and mortality were investigated using generalised linear regression model 983 
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(GLM). Odds ratios and confidence intervals were calculated from the GLM model with p-984 
values ≤ 0.05 considered significant. 985 
Approval to conduct the prospective data collection was given by the research ethics committee 986 
associated with each participating AGAR laboratory. 987 
 988 
4.5 RESULTS  989 
From 1st January 2015 to 31st December 2017 1,296 E. faecium BSI isolates were collected in 990 
the AGAR AESOPs. WGS quality control excluded 266 isolates and an additional five isolates 991 
were excluded due to ambiguous MLST alleles (two isolates with multiple copies of an allele 992 
and three isolates with truncated alleles). The remaining 1,025 isolates (332 in 2015, 320 in 993 
2016 and 373 in 2017) were used in the study. The average genome size of isolates was 994 
2,974,436bp with a standard deviation of 269,356bp. The average number of genes per isolate 995 
was 2,789 with a standard deviation of 244. 996 
For the 1,025 episodes of E. faecium bacteraemia, the average patients age was 64 years with 997 
an interquartile range of 55 and 77. The male to female ratio was approximately 1.6 and when 998 
known, the 30-day all-cause mortality was 26.2%. 999 
E. faecium isolates were collected from all Australian states and mainland territories: New 1000 
South Wales (NSW) 352 isolates; Victoria (Vic) 301; Western Australia (WA) 140; 1001 
Queensland (Qld) 85; South Australia (SA) 77; Tasmania (Tas) 34; Australian Capital Territory 1002 
(ACT) 21; and the Northern Territory (NT) 15. 1003 
Of the 1,025 isolates, 979 were categorized into 75 previously reported STs. The remaining 46 1004 
isolates consisted of 43 new MLST profiles which were designated a ST by the MLST database 1005 
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curator (https://pubmlst.org/efaecium/). From the BURST model (Figure 4.5 -Supplementary), 1006 
95.8% of isolates (982/1025), which included 83 STs were grouped into CC17. Thirty-two STs 1007 
(40 isolates) were grouped into CC94 with ST94 identified as the founder. The three remaining 1008 
isolates were singletons and a doubleton.  Overall, 11 STs (ST17, ST18, ST78, ST80, ST192, 1009 
ST203, ST262, ST555, ST796, ST1421 and ST1424) were considered as major STs (≥ 20 1010 
isolates) and all belonged to CC17 (Table 4.1). 1011 
  1012 
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Table 4.1 Eleven major sequence types (≥20 isolates) identified in the Australian Group on Antimicrobial 1013 
Resistance Australian Enterococcal Sepsis Outcome Program 2015-2017. 1014 
 ST17 ST18 ST78 ST80 ST192 ST203 ST262 ST555 ST796 ST1421 ST1424 
2015 17 5 21 28 9 33 9 43 66 45 5 
2016 40 4 11 40 5 20 9 31 47 52 16 
2017 60 11 10 35 7 10 3 17 46 52 50 
Total 117 20 42 103 21 63 21 91 159 149 71 
 1015 
  1016 
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Of the 11 major STs, ST1421 and ST796 had the most number of isolates with 149 and 159 1017 
isolates respectively. Over the three years, the number of isolates identified as ST17 and 1018 
ST1424 increased the most per year from 17 to 60 and 5 to 45 isolates respectively. Conversely, 1019 
the number of isolates identified as ST555 and ST203 decreased the most per year from 43 to 1020 
17 and 33 to 10 isolates respectively.  1021 
From the BURST analysis, the recently reported pstS-absent STs (32) were identified in three 1022 
different branches within CC17 and were separated by at least three ST nodes. The largest 1023 
group of pstS-absent STs consisted of ST1421 as the founder with ST1422, ST1423, ST1478, 1024 
ST1553 and ST1558 as single locus variants (SLVs). ST1424 and ST1559 formed the second 1025 
group while the third group consisted of a single ST1545 isolate.  1026 
Sixty-one virulence factors were identified, of which nine were present in five or more isolates. 1027 
The nine predominant virulence factors identified were: cpsF (encodes cleavage and 1028 
polyadenylation specific factor); ecbA (encodes a collagen type-V binding microbial surface 1029 
component recognizing adhesive matrix molecule [MSCRAMM]); fss3 (encodes a fibrinogen-1030 
binding MSCRAMM); psaA (encodes pneumococcal surface adhesion A); sgrA (encodes a 1031 
LPxTG surface adhesion that binds to fibrinogen and nidogen and is commonly implicated in 1032 
biofilm formation); acm (encodes a collagen binding MSCRAMM); bsh (encodes bile salt 1033 
hydrolase), bopD (putatively encodes a sugar-binding transcriptional regulator critical for the 1034 
process of biofilm);  and clpP (encodes the ClpP protease) were. The average number of 1035 
predominant virulence factors identified per isolate was 5.2. The percentage of isolates 1036 
harbouring the nine predominant virulence factors for the eleven major STs is summarized in 1037 
Table 4.2. 1038 
  1039 
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Table 4.2 Percentage of predominant virulence factors identified in the 11 major Enterococcus faecium 1040 
multilocus sequence types. 1041 
ST acm bopD bsh clpP cpsF ecbA fss3 psaA sgrA 
17 100.0 99.1 100.0 100.0 0 75.2 75.2 76.9 93.2 
18 100.0 100.0 100.0 100.0 0.0 5.0 10.0 5.0 70.0 
78 100.0 97.6 100.0 100.0 21.4 0.0 95.2 95.2 52.4 
80 100.0 100.0 99.0 100.0 0.0 1.9 46.6 44.7 97.1 
192 100.0 100.0 100.0 100.0 0.0 95.2 100.0 100.0 95.2 
203 100.0 100.0 100.0 100.0 0.0 79.4 88.9 95.2 95.2 
262 100.0 100.0 100.0 100.0 0.0 0.0 19.0 19.0 9.5 
555 98.9 100.0 100.0 100.0 0.0 0.0 100.0 96.7 94.5 
796 99.4 100.0 100.0 100.0 0.0 1.9 100.0 96.9 96.2 
1421 100.0 100.0 92.6 100.0 0.0 94.6 93.3 94.6 91.3 
1424 100.0 100.0 97.2 100.0 0.0 95.8 91.5 95.8 97.2 
 1042 
  1043 
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Twenty-six antimicrobial resistance genes were identified of which 20 were present in five or 1044 
more isolates. The 20 predominant antimicrobial resistance genes identified were: aadE, 1045 
aac(6')-aph(2''), ant(6)-Ia, aph(2'')-Ie,aph(3')-III and spc encoding aminoglycoside resistance; 1046 
cat(pC221) and cat encoding chloramphenicol resistance; tet(S), tet(L), tet(M), tet(U) encoding 1047 
tetracycline resistance; erm(A), erm(B) and erm(T) encoding macrolide, lincosamide and 1048 
streptogramin B resistance; vanA and vanB encoding glycopeptide resistance; lnu(B) encoding 1049 
lincosamide resistance; dfrG encoding trimethoprim resistance; and msrC encoding 1050 
erythromycin, macrolide and streptogramin B resistance. The average number of predominant 1051 
resistance genes identified per isolate was 6.7.  The percentage of isolates harbouring the 20 1052 
predominant antimicrobial resistance genes for the 11 major STs is summarized in Table 4.3.  1053 
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Table 4.3 Percentage of predominant resistance genes identified in the 11 major Enterococcus faecium multilocus sequence types. 1054 
 Aminoglycoside Chloramphenicol Tetracycline MLSb1 Vancomycin Trimethoprim EMSb2 Lincosamide 






III spc cat(pC221) cat tet(L) tet(M) tet(S) tet(U) erm(A) erm(B) erm(T) vanA vanB dfrG msr(C) lnu(B) 
17 11.1 0.0 27.4 5.1 70.1 1.7 0.0 0.0 19.7 33.3 0.0 55.6 1.7 79.5 12.0 1.7 12.0 29.1 100.0 0.0 
18 25.0 20.0 5.0 0.0 25.0 0.0 0.0 25.0 85.0 25.0 0.0 0.0 0.0 55.0 30.0 0.0 20.0 85.0 100.0 25.0 
78 19.0 0.0 9.5 21.4 31.0 0.0 0.0 0.0 66.7 23.8 0.0 38.1 0.0 40.5 35.7 2.4 88.1 71.4 100.0 2.4 
80 3.9 1.0 31.1 0.0 36.9 0.0 1.0 0.0 62.1 12.6 26.2 25.2 0.0 46.6 35.0 32.0 14.6 68.9 100.0 3.9 
192 0.0 0.0 71.4 0.0 100.0 0.0 0.0 0.0 14.3 4.8 0.0 4.8 0.0 100.0 0.0 0.0 0.0 0.0 100.0 0.0 
203 15.9 0.0 74.6 1.6 77.8 0.0 11.1 0.0 1.6 82.5 0.0 28.6 0.0 95.2 0.0 14.3 49.2 1.6 100.0 30.2 
262 0.0 4.8 0.0 0.0 0.0 0.0 0.0 61.9 85.7 4.8 0.0 9.5 0.0 85.7 0.0 0.0 0.0 90.5 100.0 4.8 
555 25.6 0.0 42.2 0.0 45.6 1.1 0.0 0.0 2.2 53.3 0.0 4.4 1.1 90.0 1.1 0.0 47.8 93.3 100.0 37.8 
796 38.4 0.0 3.8 0.0 3.8 1.9 0.6 0.6 0.0 95.6 0.6 30.2 1.9 90.6 0.0 0.6 95.0 97.5 100.0 1.3 
1421 8.7 0.0 0.0 0.0 91.3 97.3 0.0 0.0 10.1 6.7 0.0 34.9 94.6 96.6 2.7 74.5 0.7 92.6 99.3 0.0 
1424 4.2 0.0 0.0 0.0 69.0 94.4 0.0 0.0 22.5 2.8 2.8 29.6 93.0 91.5 0.0 60.6 1.4 97.2 100.0 0.0 
1 Macrolide, Lincosamide and Streptogramin B (MLSb)  1055 
2 Erythromycin, Macrolide and Streptogramin B (EMSb) 1056 
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Vancomycin resistance in isolates from all three years was limited to the vanA and vanB 1057 
operon. Neither vanM nor the vertically transmitted vanC operons were identified. The 1058 
proportion of E. faecium isolates harbouring the vanA operon increased throughout the study 1059 
period from 17.2% in 2015 to 22.3% in 2017 while the proportion of isolates harbouring the 1060 
vanB operon decreased from 38.3% in 2015 to 25.2% in 2017. The geographical distribution 1061 
of the proportions of van operon was different for each state and mainland territory (Table 4.4).  1062 
  1063 
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Table 4.4 The percentage of van genotypes across Australian states and mainland territories.  1064 
 ACT NSW NT Qld SA Tas Vic WA 
vanA 47.6 38.6 0.0 10.6 3.9 2.9 12.6 6.4 
vanB 4.8 13.1 73.3 32.9 46.8 32.4 53.8 8.6 
van negative 47.6 48.3 26.7 56.5 49.4 64.7 33.6 85.0 
  1065 
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A maximum likelihood phylogenetic tree was constructed based on 35,058 core single 1066 
nucleotide polymorphisms (SNPs) to determine the relatedness between isolates (Figure 4.1). 1067 
The root of the tree was placed at the most distantly related isolate (E31901_2017). Three major 1068 
clusters were observed. From the phylogenetic tree, the major STs 78, 192, 203, 262, 555, 796, 1069 
1421 appeared in one cluster; while STs, 17, 18, 80 and 1424 appeared in more than one cluster 1070 




Figure 4.1 Maximum likelihood phylogenetic tree based on single nucleotide polymorphisms grouped all Enterococcus faecium isolates into three 
clusters. From the outermost ring: Number of virulence factors, number of antimicrobial resistance genes not including the van operon, type of 
van operon and major sequence types are highlighted as per legend. 
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Table 4.5 Isolate characteristics based on the three phylogenetic clusters. 1073 




ratio (95% CI) 
Average antimicrobial 




A 30 ST17, ST18 and ST80 23.1 1.9 (0.6-5.7) 4.8 5.2 
B 104 - 13.6 ref 1.6 4.0 
2 
A 54 ST17, ST18 and ST262 24.5 2.1 (0.8-5.2) 4.7 5.2 
B 85 ST80, ST1421 and ST1424 32.5 3.1 (1.4-7.0) 5.3 5.7 
C 222 ST17, ST1421 and ST1424 33.0 3.1 (1.6-6.6) 6.9 7.7 
3 
A 73 
ST17, ST80, ST192, ST203 and 
ST1424 24.3 2.0 (0.9-4.8) 5.2 7.5 
B 69 ST17, ST80 and ST192 23.9 2.0 (0.9-4.8) 4.0 7.7 
C 71 ST203 17.2 1.3 (0.5-3.3) 5.7 7.4 
D 18 ST18 43.8 4.9 (1.5-16.2) 5.8 6.8 
E 86 ST17 and ST555 25.3 2.2 (1.0-5.0) 5.4 6.9 
F 214 
ST78, ST80, ST203, ST555 and 




Of the three clusters, cluster 1 harboured the fewest isolates, having only 134 isolates (Figure 1075 
4.2). However in terms of STs, cluster 1 was the most diverse with 84 unique STs including 1076 
the major STs 17, 18 and 80. Cluster 1 isolates could be divided into two sub-clusters: 1A and 1077 
1B. Sub-cluster 1A consisted of 30 isolates with eight STs, all members of CC17, and included 1078 
the major STs 17, 18 and 80. Sub-cluster 1B consisted of 104 isolates with 76 STs and included 1079 
all CC94 isolates, which accounted for 38.5% of isolates in the sub-cluster and, the three non-1080 




Figure 4.2 Maximum likelihood phylogenetic tree of cluster 1 isolates. From the outermost ring: Number of virulence 
factors, number of resistance genes not including the van operon, type of van operon and sequence types are highlighted 
as per legend. 
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Isolates from sub-cluster 1A harboured an average of 4.8 antimicrobial resistance genes. All 1083 
isolates in sub-cluster 1A harboured msrC and more than 80% of isolates harboured tet(L) and 1084 
dfrG. No isolate in sub-cluster 1A harboured the aadE, cat(pC221) or tet(S) antimicrobial 1085 
resistance genes. The vanA and vanB operon was identified in 6.7 % and 10.0% of isolates 1086 
respectively. No isolate harboured both van operons. Sub-cluster 1A isolates harboured an 1087 
average of 5.2 virulence factors. All isolates in sub-cluster 1A harboured the acm, bsh and clpP 1088 
and more than 80% harboured bopD and sgrA. No isolates in sub-cluster 1A harboured the 1089 
cpsF virulence factor. When known, the 30-day all-cause mortality of patients with sub-cluster 1090 
1A isolates was 23.1%. When compared to sub-cluster 1B, which had the lowest mortality of 1091 
all sub-clusters at 13.6%, the odds ratio for mortality was calculated at 1.9 (CI: 0.6-5.7). The 1092 
difference in 30-day all-cause mortality between sub-clusters 1A and 1B was not significant (p 1093 
= 0.25). 1094 
Isolates from sub-cluster 1B harboured an average of 1.6 antimicrobial resistance genes. More 1095 
than 80% of isolates harboured msrC. No isolates in sub-cluster 1B harboured the vanA, vanB, 1096 
ant(6)-la, aph(2”)-le and tet(S) resistance genes. Sub-cluster 1B isolates harboured an average 1097 
of 4.0 virulence factors. All isolates harboured bopD and clpP, and more than 80% harboured 1098 
bsh. None of the isolates in sub-cluster 1B harboured the psaA virulence factor.  1099 
  1100 
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Cluster 2 consisted of 361 isolates with 22 STs, all part of CC17, and included five major STs: 1101 
18, 262, 80, 1424, 1421 (Figure 4.3). Cluster 2 isolates could be divided into three sub-clusters: 1102 
2A, 2B and 2C. Sub-cluster 2A, consisted of 54 isolates with six STs including the major STs 1103 
17, 18 and 262. Isolates from sub-cluster 2A were collected from all Australian regions except 1104 
the ACT. Sub-cluster 2B, consisted of 85 isolates with 12 STs including major STs 1421, 1424 1105 
and 80. Isolates from sub-cluster 2B were collected from across Australia. Sub-cluster 2C, 1106 
consisted of 222 isolates with eight STs including major STs 17, 1421 and 1424. Isolates from 1107 




  1110 
Figure 4.3 Maximum likelihood phylogenetic tree of cluster 2 isolates. From the outermost ring: Number of virulence 
factors, number of resistance genes not including the van operon, type of van operon and sequence types are highlighted 
as per legend. 
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Isolates from sub-cluster 2A harboured an average of 4.7 antimicrobial resistance genes. All 1111 
isolates in sub-cluster 2A harboured msrC and more than 80% of isolates harboured dfrG. No 1112 
isolate in sub-cluster 1A harboured aph(2”)-le, erm(A), tet(S) or spc. The vanA and vanB 1113 
operon was identified in 1.9 % and 16.7% of isolates respectively. Sub-cluster 2A isolates 1114 
harboured an average of 5.2 virulence factors. All isolates in sub-cluster 2A harboured acm, 1115 
bopD, bsh and clpP. None of the remaining predominant virulence factors were identified in 1116 
more than 80% of isolates. No isolate in sub-cluster 2A harboured cpsF. When known, the 30-1117 
day all-cause mortality of patients with 2A isolates was 24.5%. Compared to sub-cluster 1B 1118 
isolates the odds ratio for mortality was calculated at 2.1(CI: 0.5-5.2). The difference in 30-day 1119 
all-cause mortality between sub-clusters 2A and 1B was not significant (p = 0.12). 1120 
Isolates from sub-cluster 2B harboured an average of 5.3 antimicrobial resistance genes. All 1121 
isolates in sub-cluster 2B harboured msrC and more than 80% of isolates harboured dfrG. No 1122 
isolates in sub-cluster 2B harboured aph(2”)-le or cat. The vanA and vanB operon was 1123 
identified in 28.2 % and 14.1% of isolates respectively. Sub-cluster 2B isolates harboured an 1124 
average of 5.7 virulence factors. All isolates in sub-cluster 2B harboured bopD and clpP and 1125 
more than 80% of isolates harboured acm, bsh and sgrA. No isolates in sub-cluster 2B 1126 
harboured the cpsF virulence factor. When known, the 30-day all-cause mortality of patients 1127 
with sub-cluster 2B isolates was 32.5%. Compared to sub-cluster 1B isolates the odds ratio for 1128 
mortality was calculated at 3.1 (CI: 1.4-7.0). The difference in 30-day all-cause mortality 1129 
between sub-clusters 2B and 1B was significant (p = 0.005). 1130 
Isolates from sub-cluster 2C harboured an average of 6.9 antimicrobial resistance genes. More 1131 
than 80% of isolates harboured dfrG, erm(A), erm(B), msrC, spc and aph(3’)-III. No isolates 1132 
in sub-cluster 2C harboured aadE, ant(6)-la, aph(2”)-le, cat(p221), cat, lnu(B) or tet(S). The 1133 
vanA and vanB operon was identified in 68.0 % and 0.9% of isolates respectively. Sub-cluster 1134 
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2C isolates harboured an average of 7.7 virulence factors. All isolates in sub-cluster 2C 1135 
harboured acm, bopD and clpP and more than 80% of isolates harboured bsh, ecbA, fss3, psaA 1136 
and sgrA. No isolates in sub-cluster 2A harboured the cpsF virulence factor. When known, the 1137 
30-day all-cause mortality of patients with sub-cluster 2C isolates was 33.0%. Compared to 1138 
sub-cluster 1B isolates the odds ratio for mortality was calculated at 3.1 (CI: 1.6-6.6). The 1139 
difference in 30-day all-cause mortality between sub-clusters 2C and 1B was significant (p = 1140 
0.001). 1141 
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Cluster three was the largest cluster consisting of 530 isolates with 20 STs (Figure 4.4). All 1143 
STs identified in cluster 3 were part of CC17 and included the major STs 17, 78, 80, 203, 555, 1144 
796, 1424, 1421. Cluster 3 isolates could be divided into six sub-clusters: 3A to 3F. Sub-cluster 1145 
3A, consisted of 73 isolates with six STs including the major STs 17, 80, 192, 203 and 1424. 1146 
Isolates from sub-cluster 3A were collected from all Australian regions except SA, ACT and 1147 
NT. Sub-cluster 3B, consisted of 69 isolates with three STs including the major STs 17, 80 and 1148 
192. Isolates from sub-cluster 3B were collected from all Australian regions except NSW, Vic 1149 
and ACT. Sub-cluster 3C, consisted of 71 isolates with seven STs including the major ST 1150 
ST203. Isolates from sub-cluster 3C were collected from all Australian regions except the NT. 1151 
Sub-cluster 3D, consisted of 18 isolates with four STs including the major STs 18 and 80. 1152 
Isolates from sub-cluster 3D were collected from all Australian regions except the NT and 1153 
ACT. Sub-cluster 3E, consisted of 86 isolates, with two major STs 17 and 555. Isolates from 1154 
sub-cluster 3E were collected from all Australian regions except the ACT, Qld and Vic. Sub-1155 
cluster 3F, consisted of 214 isolates, with eight STs including the major STs 78, 80, 203, 555 1156 
and 796. Isolates from sub-cluster 3F were collected from all Australian regions except the 1157 
ACT. 1158 
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1160 Figure 4.4 Maximum likelihood phylogenetic tree of isolates in cluster 3. From the outermost ring: Number of virulence factors, 
number of resistance genes not including the van operon, type of van operon and sequence types are highlighted as per legend. 
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Isolates from sub-cluster 3A harboured an average of 5.2 antimicrobial resistance genes. All 1161 
isolates in sub-cluster 3A harboured msrC and more than 80% of isolates harboured ant(6)-IA, 1162 
aph(3”)-III and erm(B). No isolates in sub-cluster 3A harboured aadE, aph(2”)-le, cat(p221), 1163 
cat, erm(A) or spc. The vanA and vanB operon was identified in 19.2 % and 15.1% of isolates 1164 
respectively. Sub-cluster 3A isolates harboured an average of 7.5 virulence factors. All isolates 1165 
in sub-cluster 3A harboured acm, bopD and fss3 and more than 80% of isolates harboured bsh, 1166 
clpP, psaA and sgrA. No isolates in sub-cluster 3A harboured the cpsF virulence factor. When 1167 
known, the 30-day all-cause mortality of patients with sub-cluster 3A isolates was 24.3%. 1168 
Compared to sub-cluster 1B isolates the odds ratio for mortality was calculated at 2.0 (CI: 0.9-1169 
4.8). The difference in 30-day all-cause mortality between sub-clusters 3A and 1B was not 1170 
significant (p = 0.10). 1171 
Isolates from sub-cluster 3B harboured an average of 4.0 antimicrobial resistance genes. All 1172 
isolates in sub-cluster 3B harboured msrC and more than 80% of isolates harboured aph(3’)-1173 
III and erm(B). No isolate in sub-cluster 3B harboured aadE, aph(2”)-Ie, cat(p221), cat, 1174 
erm(A), erm(T), spc or tet(L). The vanA and vanB operon was identified in 11.2 % and 2.9% 1175 
of isolates respectively. Sub-cluster 3B isolates harboured an average of 7.7 virulence factors. 1176 
All isolates in sub-cluster 3B harboured acm, bopD and clpP and more than 80% of isolates 1177 
harboured bsh, fss3, psaA and sgrA. No isolates in sub-cluster 3B harboured the cpsF virulence 1178 
factor.  When known, the 30-day all-cause mortality of patients with sub-cluster 3B isolates 1179 
was 23.9%. Compared to sub-cluster 1B isolates the odds ratio for mortality was calculated at 1180 
2.0 (CI: 0.9-4.8). The difference in 30-day all-cause mortality between sub-clusters 3B and 1B 1181 
was not significant (p = 0.11). 1182 
Isolates from sub-cluster 3C harboured an average of 5.7 antimicrobial resistance genes. All 1183 
isolates in sub-cluster 3C harboured msrC and more than 80% of isolates harboured erm(B) 1184 
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and tet(M). No isolates in sub-cluster 3C harboured aadE, aph(2”)-le, cat, erm(A), erm(T), 1185 
spc, tet(L) or tet(S). The vanA and vanB operon was identified in 12.9 % and 47.1% of isolates 1186 
respectively. Sub-cluster 3C isolates harboured an average of 7.4 virulence factors. All isolates 1187 
in sub-cluster 3C harboured acm, bsh and clpP and more than 80% of isolates harboured bopD, 1188 
fss3, psaA and sgrA. No isolate in sub-cluster 3B harboured the cpsF virulence factor. When 1189 
known, the 30-day all-cause mortality of patients with sub-cluster 3C isolates was 17.2%. 1190 
Compared to sub-cluster 1B isolates the odds ratio for mortality was calculated at 1.3 (CI: 0.5-1191 
3.3). The difference in 30-day all-cause mortality between sub-clusters 3C and 1B was not 1192 
significant (p = 0.55). 1193 
Isolates from sub-cluster 3D harboured an average of 5.8 antimicrobial resistance genes. All 1194 
isolates in sub-cluster 3D harboured msrC and more than 80% of isolates harboured ant(6)-Ia, 1195 
aph(3”)-III and erm(B). No isolates in sub-cluster 3D harboured aadE, aph(2”)-Ie, 1196 
cat(pC221), erm(A), lnu(B), spc or tet(S). The vanA and vanB operon was identified in 5.6% 1197 
and 11.1% of isolates respectively. Sub-cluster 3D isolates harboured an average of 6.8 1198 
virulence factors. All isolates in sub-cluster 3D harboured acm, bopD and clpP and more than 1199 
80% of isolates harboured bsh, psaA and sgrA. No isolates in sub-cluster 3D harboured the 1200 
cpsF virulence factor. When known, the 30-day all-cause mortality of patients with 3D isolates 1201 
was 43.8%. Compared to sub-cluster 1B isolates the odds ratio for mortality was calculated at 1202 
4.9 (CI: 1.5-16.2). The difference in 30-day all-cause mortality between sub-clusters 3D and 1203 
1B was significant (p = 0.008). 1204 
Isolates from sub-cluster 3E harboured an average of 5.4 antimicrobial resistance genes. All 1205 
isolates in sub-cluster 3E harboured msrC and more than 80% of isolates harboured dfrG and 1206 
erm(B). No isolates in sub-cluster 3E harboured aadE, aph(2”)-Ie, cat(pC221), cat, vanA or 1207 
tet(S). The vanB operon was identified in 48.8% of isolates. The vanA operon was not 1208 
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identified in sub-cluster 3E. Sub-cluster 3E isolates harboured an average of 6.9 virulence 1209 
factors. All isolates in sub-cluster 3E harboured bopD, bsh, clpP and fss3 and more than 80% 1210 
of isolates harboured acm, psaA and sgrA. No isolates in sub-cluster 3E harboured the cpsF or 1211 
ecbA virulence factors. When known, the 30-day all-cause mortality of patients with sub-1212 
cluster 3E isolates was 25.3%. Compared to sub-cluster 1B isolates the odds ratio for mortality 1213 
was calculated at 2.2(CI: 1.0-5.0). The difference in 30-day all-cause mortality between sub-1214 
clusters 3E and 1B was not significant (p = 0.06). 1215 
Isolates from sub-cluster 3F harboured an average of 5.6 antimicrobial resistance genes. All 1216 
isolates in sub-cluster 3F harboured msrC and more than 80% of isolates harboured dfrG, 1217 
erm(B) and vanB. No isolates in sub-cluster 3F harboured the aadE resistance gene. The vanA 1218 
and vanB operon was identified in 0.9 and 92.1% of isolates respectively. Sub-cluster 3F 1219 
isolates harboured an average of 6.9 virulence factors. All isolates in sub-cluster 3F harboured 1220 
bsh and clpP and more than 80% of isolates harboured acm, bopD, fss3, psaA and sgrA. When 1221 
known, the 30-day all-cause mortality of patients with sub-cluster 3F isolates was 26.6%. 1222 
Compared to sub-cluster 1B isolates the odds ratio for mortality was calculated at 2.3(CI: 1.2-1223 
4.9). The difference in 30-day all-cause mortality between sub-clusters 3F and 1B was 1224 
significant (p = 0.02). 1225 
Geographically, the distribution of van genes and sequence types varied. In NSW, 38.6% and 1226 
13.1% of isolates harboured the vanA and vanB operon respectively. An additional isolate 1227 
harboured both vanA and vanB operons. The most frequent ST amongst the NSW isolates was 1228 
ST1421 accounting for 32.4% of isolates. Overall, 54% of isolates from NSW were identified 1229 
in sub-cluster 2C. 1230 
In Vic, 12.6% and 53.8% of isolates harboured the vanA and vanB operon respectively. An 1231 
additional five isolates harboured both the vanA and vanB operons. Except for a pair of closely 1232 
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related ST80 isolates, isolates harbouring both operons were from different STs and unrelated 1233 
phylogenetically. The most frequent ST amongst the Vic isolates was ST796 accounting for 1234 
44.5% of isolates. Overall, 47.2% of isolates from Vic were identified in sub-cluster 3D. 1235 
In Qld, 10.6% and 32.9% of isolates harboured the vanA and vanB operon respectively. The 1236 
most frequent ST amongst the Qld isolates was ST17 accounting for 29.4% of isolates. Overall, 1237 
23.5% and 22.4% of isolates from Qld were identified in sub-cluster 3A and 3F respectively. 1238 
In WA, only 6.4% and 8.6% of isolates harboured the vanA and vanB operon respectively. The 1239 
most frequent ST amongst the WA isolates was ST17 accounting for 35% of isolates. Overall, 1240 
40.0% of isolates from WA were identified in sub-cluster 3B. 1241 
In SA, 3.9% and 46.8% of isolates harboured the vanA and vanB operon respectively. The 1242 
most frequent ST amongst the SA isolates was ST555 accounting for 45.5% of isolates. 1243 
Overall, 45.5% of isolates from SA were identified in sub-cluster 3E. 1244 
In Tas, 2.9% and 32.4% of isolates harboured the vanA and vanB operon respectively. The 1245 
most frequent ST amongst the Tas isolates was ST796 accounting for 29.4% of isolates. 1246 
Overall, 23.5% of isolates from Tas were identified in sub-cluster 3B. 1247 
In the NT, 73.3% of isolates harboured the vanB operon. The most frequent ST amongst the 1248 
NT isolates was ST555 accounting for 66.7% of isolates. Overall, 66.7% of isolates from NT 1249 
were identified in sub-cluster 3E. 1250 
In the ACT, 47.6% and 4.8% of isolates harboured the vanA and vanB operon respectively. 1251 
The most frequent ST amongst the ACT isolates was ST1421 accounting for 57.1% of isolates. 1252 
Overall, 61.9% of isolates from ACT were identified in sub-cluster 2C. 1253 
  1254 
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4.6 DISCUSSION 1255 
In 2011, 36.5% of Australian E. faecium bacteraemia isolates were identified as vancomycin 1256 
non-susceptible, of which 98.4% harboured the vanB operon (33). Supported by AESOP 1257 
reports, the high prevalence of VREfm has been a growing trend in Australian hospitals over 1258 
the last decade. In this study, we employed WGS as a screening tool in the surveillance of 1259 
1,025 BSI associated E. faecium collected across Australia from 2015 to 2017. Using 1260 
bioinformatics, we have demonstrated E. faecium epidemiology is heterogenous across 1261 
Australia with a mixture of strains harbouring unique genetic compositions that are constantly 1262 
evolving in each region. When studied on a national level, Australian E. faecium BSI isolates 1263 
can be classified into three broad molecular clusters and further divided into eleven sub-1264 
clusters. In addition, by pairing genomic features with molecular phylogeny we have identified 1265 
key phylogenetic clusters with increased clinical significance with respect to 30-day all-cause 1266 
mortality. 1267 
Focusing on the high prevalence of VREfm in Australia, the majority of vancomycin resistant 1268 
isolates were associated with sub-clusters 2 and 3. Within clusters 2 and 3, sub-clusters 2C and 1269 
3F had the highest proportion of vancomycin resistant isolates. Aside from the high van operon 1270 
carriage, sub-cluster 2C had the most number of isolates, the highest number of average 1271 
antimicrobial resistance and virulence genes per isolate, and the second highest 30 day all-1272 
cause mortality. Similarly, sub-cluster 3F, which had the second highest number of isolates, 1273 
harboured a higher than average number of antimicrobial resistance and virulence genes. 1274 
Conversely, isolates in sub-cluster 1B had the lowest numbers of antimicrobial resistance and 1275 
virulence genes and the lowest 30-day all-cause mortality. 1276 
Comparing sub-clusters, we observed an increase in the number of clonal isolates, namely 1277 
ST1421 and ST796, in the two van operon dominant sub-clusters, 2C and 3F respectively. In 1278 
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contrast we observed a low clonality of isolates and the absence of the van operon in sub-cluster 1279 
1B. Other than a high prevalence of the van operon, we were not able to identify additional 1280 
antimicrobial resistance or virulence genes that offered sub-clusters 2C and 3F an advantage 1281 
over the other sub-clusters. A significant difference in the 30-day all-cause mortality was 1282 
observed in the four predominant VREfm sub-clusters (2B, 2C, 3D and 3F).  1283 
In sub-clusters 2C and 3F, we observed a dominance of the vanA operon and vanB operon 1284 
respectively. However, the dominance of a particular van operon was not observed throughout 1285 
a cluster. From the phylogenetic tree of clusters 2 and 3, basal isolates in sub-clusters 2A and 1286 
3A predominantly harboured a mixture of van operon type. With the exception of sub-cluster 1287 
3B, when moving further from the root in clusters 2 and 3, a gradual and sequential increase in 1288 
the prevalence of a particular van operons was observed.  1289 
Over the three-year study period, we observed a decrease in the proportion of isolates 1290 
harbouring the vanB operon but an increase in isolates harbouring the vanA operon. The result, 1291 
coupled with the 2011 report identifying a 98.4% prevalence in vanB type VREfm (34), 1292 
indicates a shift in trend towards vanA VREfm in Australia. 1293 
Although E. faecium isolates were collected from every region in Australia, limitations of this 1294 
study include the difference in the number of participating laboratories and population 1295 
demographics in each region. Additionally, frequent patient transfers between NT and SA, Tas 1296 
and Vic, and the ACT and NSW, has resulted in major cross regional of patients. Therefore, in 1297 
this study, we are unable to make accurate observations comparing the regional distribution of 1298 
isolates across Australia. However, for most regions, we did observe specific region-dominant 1299 
sub-clusters accounting for at least 45% of isolates. Additionally, we observed isolates from 1300 
cluster 2C were collected in the fewest locations (NSW, Vic, SA and ACT) suggesting a more 1301 
confined geographical distribution.  1302 
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In our study, we observed several discrepancies between the relationship of STs described by 1303 
the BURST diagram compared to SNP based molecular phylogeny. For example, isolates in 1304 
sub-cluster 2C typed as ST1421 and ST1424 and isolates in sub-cluster 3F typed as ST203 and 1305 
ST796 were observed to be distantly related by BURST but closely related by SNP phylogeny. 1306 
SNP inferred isolate relationship offers a much higher resolution. As such, the use of BURST 1307 
modelling may not be accurate in depicting relationships between E. faecium strains. 1308 
In conclusion, our study has shown E. faecium isolates from 2015 to 2017 causing BSI in 1309 
Australia could be classified into three phylogenetic clusters. Moreover, each cluster can be 1310 
characterized by a dominant van operon (or the lack of one) which we have shown to be key 1311 
in the dissemination of isolates. Our findings also show, unlike in 2011 when VREfm in 1312 
Australia was primarily due to the vanB operon, the presence of a highly successful vanA 1313 
dominant strain identified in sub-cluster 2C have resulted in the co-dominance of vanA and 1314 
vanB VREfm in Australia. Our analysis has highlighted clinically important strains of E. 1315 
faecium in sub-cluster 2C and 3F which should be closely monitored in future surveillance. 1316 
With the phylogeny of VREfm in Australia established in this study, future surveillance can 1317 
now identify the introduction or emergence of new E. faecium strains with a much higher 1318 
resolution compared to MLST. Additionally, with regular timely monitoring, individual 1319 
hospitals can use the detection of clinically important VREfm strains, such as those identified 1320 
in sub-cluster 2C and 3F as early warnings of potential outbreaks and therefore appropriate 1321 
infection control procedures could be commenced earlier than preboiusly. Further studies of 1322 
the van operon and genes associated with the operon will contribute to our understanding of 1323 
the evolution of enterococci in the hospital environment and assist in the implementation of 1324 
successful control strategies. 1325 
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Figure 4.5 (Supplementary) eBURST of the Australian Group on Antimicrobial Resistance Australian 1419 
Enterococcal Sepsis Outcome Programs 2015-2017 Enterococcus faecium multilocus sequence types 1420 
and isolates from the reference database (https://pubmlst.org). Lines between nodes indicate single 1421 
locus variants, circle size indicates isolate numbers and yellow and blue circles indicate founders  1422 
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5.2 ABSTRACT 1439 
Background 1440 
Vancomycin resistance is conferred in E. faecium by the expression of the van operon. 1441 
Clinically significant van genotypes vanA and vanB are often located on mobile genetic 1442 
elements facilitating the transmission of vancomycin resistance to other Gram-positive 1443 
bacteria. 1444 
Objectives 1445 
To understand the transmission of vancomycin resistance within E. faecium in Australia by 1446 
typing the vanA and vanB operons and comparing operon types to single nucleotide 1447 
polymorphisms (SNPs) within the van operon.  1448 
Methods 1449 
Whole genome sequencing was performed on E. faecium isolates collected as part of the 2015 1450 
-2017 Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome 1451 
Program. Raw sequence reads from vancomycin resistant isolates were mapped against 1452 
reference van operons and compared to phylogenetic analysis inferred from SNPs. 1453 
Results 1454 
Five IS elements were identified within the vanA operon and three were identified in the vanB 1455 
operon. Using the IS elements present in combination with the van genes, eight vanA operon 1456 




SNP inferred phylogeny of the van operons suggests for isolates with the same multilocus 1459 
sequence type vertical transmission of the van operons has occurred. Operons identified in the 1460 
major STs were not closely related to a collection of international reference operons. 1461 
  1462 
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5.3 INTRODUCTION 1463 
Globally antimicrobial resistant bacteria pose a serious threat to public health (1). Identified as 1464 
a leading cause of nosocomial infections, E. faecium is an opportunistic pathogen that can 1465 
rapidly acquire resistance to multiple antimicrobial classes (2). Arguably the most concerning, 1466 
is the acquisition of resistance to the glycopeptide antimicrobial, vancomycin. Vancomycin is 1467 
a clinically important drug listed as an essential medicine by the World Health Organization 1468 
and is used in the treatment of many severe Gram-positive bacterial infections 3. 1469 
Vancomycin resistance in E. faecium is conferred by a series of regulatory, essential and 1470 
accessory genes within the van operon. Typically, clinical strains of vancomycin resistant E. 1471 
faecium (VREfm) harbour the vanA or vanB genotypes (4). Operons of both genotypes are 1472 
composed of seven genes that function and are regulated in generally the same way but are 1473 
different in their arrangement of genes. For vanA operon the genes are ordered, vanR – vanS – 1474 
vanH – vanA – vanX – vanY – vanZ, while for the vanB operon the gene order is, vanRB – vanSB 1475 
– vanYB – vanWB - vanHB – vanB – vanXB (4).  1476 
The expression of vanA and vanB type resistances are regulated by their respective vanR/vanS 1477 
and vanRB/vanSB genes providing a two-component signal transduction system composed of a 1478 
membrane-associated sensor kinase (vanS and vanSB) and a cytoplasmic response regulator 1479 
(vanR and vanRB) (4). The phosphorylated regulators bind to the regulatory region of 1480 
promoters located upstream of vanR and vanH in the vanA operon and vanRB and vanY in the 1481 
vanB operon resulting in transcriptional activation of the regulatory and resistance genes (5). 1482 
The vanA and vanB operons each carry three essential genes; vanH – vanA - vanX in the vanA 1483 
operon and vanHB - vanB - vanXB, in the vanB operon.  The three genes are necessary for 1484 
conferring vancomycin resistance by the replacement of vancomycin binding sites D-Ala-D-1485 
Ala with D-Ala-D-Lac in peptidoglycan precursors. An additional D,D-carboxypepidase 1486 
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encoded by vanY/vanYB cleaves the C-terminus of late membrane-bound peptidoglycan 1487 
precursors to complete the removal of regular vancomycin binding sites (6). The additional 1488 
vanZ found in vanA operons confers resistance toward the glycopeptide antimicrobial, 1489 
teicoplanin. The vanW gene found in the vanB operon shares little sequence homology with 1490 
vanZ and has no known function.  1491 
The A and B van operons are located on mobile genetic elements which can be shared amongst 1492 
bacteria. The vanA operon is typically located on plasmids within the transposon, Tn1546, 1493 
whist the vanB operon can usually be found on the chromosome or plasmids within the 1494 
transposon, Tn1547 or Tn1549. 1495 
In Australia the Australian Group on Antimicrobial Resistance (AGAR) Australian 1496 
Enterococcal Sepsis Outcome Program (AESOP) monitors and reports nationwide on the 1497 
prevalence of vancomycin resistant E. faecium (VREfm) collected from patients with 1498 
enterococcal blood stream infections (BSIs). Since 2013, over 40% of E. faecium BSI have 1499 
been reported vancomycin resistant (7-10). Previously, VREfm in Australia typically 1500 
harboured the vanB operon (11).  However, it has recently been reported that almost half of 1501 
VREfm in Australia now harbor the vanA operon (8).   1502 
In this study, we investigated the structure and elements found in the vanA and vanB operons 1503 
present in VREfm BSIs in Australia. We then compared the operons to a collection of 1504 
international reference operons to determine if operons in Australia are related. 1505 
  1506 
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5.4 MATERIALS AND METHODS 1507 
Sample Collection: Isolates were collected by participating hospitals from all Australian states 1508 
and mainland territories as part of the 2015-2017 AGAR AESOP (7,9,12). Samples were 1509 
obtained from unique individual patients with enterococcal BSI.  1510 
Diagnostics: Samples were cultured on blood agar and isolates were identified by MALDI-1511 
TOF mass spectrometry (Bruker Corporation, United States). Susceptibility testing was 1512 
performed on all isolates using either the VITEK® 2 (bioMérieux, France) or Phoenix™(BD, 1513 
United States) automated systems. Isolates identified as E. faecium were referred to the 1514 
Antimicrobial Resistance and Infectious Diseases Research Laboratory for whole genome 1515 
sequencing (WGS). 1516 
DNA extraction: Isolates received at the reference laboratory were sub-cultured on blood agar. 1517 
One to three colonies were selected for DNA extraction performed with the MagMAX™ DNA 1518 
multi-sample ultra kit (ThermoFisher Scientific, United States) as per the manufacturers 1519 
protocol with the MagMAX™ Express automated system. DNA concentrations were checked 1520 
and normalized using the Qubit fluorometric quantitation system (Thermo Fisher, United 1521 
States). 1522 
Library and sequencing: Sequencing libraries were prepared in batches with the Nextera® XT 1523 
DNA Sample Preparation Kit (Illumina, United States) according to manufacturer’s protocol. 1524 
DNA fragment sizes in prepared libraries were checked using the LabChip GX II Touch system 1525 
(PerkinElmer, United States). Checked libraries were pooled and sequenced on the MiSeq or 1526 
NextSeq 500 platform (Illumina, United States) based on the 300bp and 150bp chemistry 1527 
respectively as per described protocol. 1528 
98 
 
Bioinformatics: Raw sequence data was quality checked to ensure a minimum of 40x depth 1529 
and greater than 50% sequence identity with the reference E. faecium genome, AUS0004 1530 
(RefSeq accession: GCA_000250945.1). Raw sequencing reads were cleaned using 1531 
Trimmomatic V0.38 (13) and assembled using SPAdes (14) de novo assembler. To locate 1532 
isolates with van operons, sequences were scanned using ABRicate V0.8.7 in tandem with the 1533 
ResFinder (21/01/2019) (15) database for genes in both van genotypes. The multilocus 1534 
sequence type (ST) for each isolate was determined using the scheme described by Homan et 1535 
al. (16) with sequence definitions hosted on the BIGSdb database (17) 1536 
(https://pubmlst.org/software/database/bigsdb/).  1537 
Van operon: Raw sequences of isolates identified with van genes were mapped to the model 1538 
operons in geneious prime 2019.0.4 (https://www.geneious.com). The van operon was defined 1539 
as the genetic sequence beginning at the promoter, PvanR and PvanRB to vanZ and vanXB for 1540 
the vanA operon and the vanB operon respectively. If gaps or regions of mismatched sequences 1541 
to the model reference was identified, a new operon type was constructed in silico. To construct 1542 
the new operon type in silico, terminal nucleotide sequences of assembled contigs were used 1543 
to identify insertion sequences by searching against the IS finder (18) database or BLAST (19) 1544 
for known IS elements. Identified IS elements were manually aligned into the reference 1545 
operons to construct the new reference operon type. Raw sequencing reads from isolates were 1546 
then mapped against the new operon type to ensure continuous coverage and accurate mapping 1547 
of reads were observed throughout the new reference. Promoter regions were annotated in 1548 
silico using sequences in Table 5.1. 1549 
  1550 
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Table 5.1 List of promoter sequences identified within the vanA and van B operon. 1551 
Van Operon Promoter  Sequence  
vanA PvanR  5’-TCTTAAGAAATTC-3’ (20) 
 PvanH 1  5’-TTTAGGAAAAT-3’ 
 PvanH  2  5’-TTAGGAAATTAA-3’ 
vanB PvanRB  5’-TCTGTAGTTTCCCTGTAG-3’ (21) 
 PvanY 1  5’-TCTGTAGTTTTCCTGTAG-3’ 
 PvanY 2  5’-TCTGTACTTTCCCTGTAG-3’ 
  1552 
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Single nucleotide polymorphisms (SNPs) were identified within the van operons using Snippy 1553 
(22). A maximum likelihood phylogenetic inference was performed with RAxML (23) based 1554 
on the GTRCAT model with bootstrap values set at 1000. Additional information regarding 1555 
antimicrobial susceptibility, location and collection dates were performed and collected as part 1556 
of the 2015-2017 AGAR AESOP (7, 9, 12). 1557 
Reference sequences. High quality international vanA and vanB operon sequences were 1558 
accessed from NCBI and used as reference for comparison. Detailed information on 1559 
international sequences used are summarized in Table 5.4-Supplementary.  1560 
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5.5 RESULTS 1561 
From 1,025 E. faecium whole genome sequences collected in the 2015 to 2017 AGAR AESOP, 1562 
525 van operons were identified in 519 isolates. Two hundred and six (57 in 2015, 66 in 2016 1563 
and 83 in 2017) isolates harbored the vanA operon and 307 isolates (127 in 2015, 86 in 2016 1564 
and 94 in 2017) harbored the vanB operon only. Six isolates harbored both vanA and vanB 1565 
operons. The vanA operon was identified in isolates from 14 STs and the vanB operon was 1566 
identified in 20 STs.  1567 
5.5.1 vanA operon 1568 
In addition to the seven genes which form part of the vanA operon, five IS elements were 1569 
identified: IS1542, IS1216E, IS1251, IS1380 and ISEfa4. All vanA operons harbored IS 1570 
elements. Using a combination of the IS elements and the van genes present, eight vanA operon 1571 
types were identified (1A to 8A) (Figure 5.1). The majority of isolates (68.4%) harbored the 1572 
3A vanA operon type. The three most frequent locations for the IS elements within the vanA 1573 
operon were the intergenic regions between PvanR and vanR; vanS and PvanH; and vanX and 1574 
vanY. Two isolates were the exception.  For the 6A vanA operon type isolate the IS element, 1575 
IS1216E, was located downstream of PvanH. For the 7A vanA operon type isolate, the IS 1576 
element, IS1216E, was located between vanR and vanS. The accessory gene, vanZ gene, was 1577 
absent in vanA operon types 3A, 6A and 7A. The vanY and vanZ accessory genes, were absent 1578 
in the 8A vanA operon type. 1579 
 1580 
  1581 
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Figure 5.1 The model vanA operon without insertion sequences followed by eight types of vanA operon 
identified in 2015-2017 Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis 
Outcome Program isolates. 
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Isolates were classified as vancomycin susceptible if the minimum inhibitory concentration 1583 
(MIC) was ≤ 4 µg/ml as per the CLSI guidelines (24). The 3A vanA operon type, identified in 1584 
nine STs had variable MICs ranging from ≤0.5 to ≥16 µg/ml (Table 5.2). Isolates harboring the 1585 
1A, 2A, 4A, 7A and 8A vanA operon types all had a vancomycin MICs of ≥16 µg/ml. Except 1586 
for isolates harboring the 6A vanA operon type, all vanA operon types consisted of isolates 1587 
that were able to confer ≥16 µg/ml MIC to vancomycin. The vanA operon in isolates with a 1588 
vancomycin susceptible phenotype did not share similar SNP mutations and were not closely 1589 
related phylogenetically (Figure 5.5-Supplementary) 1590 
The vanZ gene within the vanA operon encodes teicoplanin resistance. Isolates were classified 1591 
as teicoplanin susceptible if the MIC was ≤8 µg/ml, as per the CLSI guidelines (24). Except 1592 
for isolates harboring the 6A vanA operon type, all vanA operon types were able to confer ≥16 1593 
µg/ml MIC to teicoplanin. Isolates harboring vanA operon types 1A, 2A, 4A and 7A had ≥16 1594 
µg/ml teicoplanin MICs while isolates harboring vanA operon types 3A, 5A and 8A had 1595 
variable teicoplanin MICs. The vanA operon in isolates with a teicoplanin susceptible 1596 
phenotype did not share similar SNP mutations. 1597 
  1598 
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Table 5.2. Summary of sequence types, vancomycin and teicoplanin minimum inhibitory concentrations identified in isolates harbouring the vanA operon 1599 
collected from the 2015-2017 Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Program. 1600 
 1601 
  1602 





1A 80 ≥16 ≥16 7 (3.3) 
2A 80, 203, 252, 796 ≥16 ≥16 11 (5.2) 
3A 78, 80, 233, 1421, 1424, 1478, 1553, 1558, 1559 ≤0.5, 1, 8, ≥16 ≤1, 4, 8, ≥16 145 (68.4) 
4A 17, 80, 203, 546, 1424 ≥16 ≥16 25 (11.8) 
5A 17,1478 ≤0.5, ≥16 ≤1, ≥16 3 (1.4) 
6A 1424 ≤0.5 ≤1 1 (0.5) 
7A 1421 ≥16 ≥16 1 (0.5) 
8A 1421,1478 ≥16 1, 4, ≥16 19 (9.0) 
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The five IS elements identified in the AESOP vanA E. faecium isolates were also identified in 1603 
the international reference operons. The 3A, 4A and 8A vanA operon types were identified in 1604 
31.6%, 42.1%, 5.3% of the international isolates. Four international vanA operons did not 1605 
harbor configurations identified in the AESOP isolates. Three isolates did not harbor any IS 1606 
elements, while the fourth isolate had a unique operon configuration with two IS elements 1607 
(vanR – vanS - IS1251 – vanH – vanA – vanX - IS1216E), which was most similar to a 1608 
combination of the 4A and 8A vanA operon types. The majority of vanA operons from ST1421 1609 
and ST1424 AESOP isolates were not closely related to international reference operons. 1610 
The SNP inferred maximum likelihood phylogenetic tree was rooted at an international 1611 
reference isolate (Accession:MG674582) harboring the model vanA operon (Figure 5.2). 1612 
Overall, STs harboring the same vanA operon type were clustered together on the phylogenetic 1613 
tree. For example, the majority of ST80 isolates mostly harbored the 4A and 1A type operon  1614 




  1617 
Figure 5.2 Single nucleotide polymorphism inferred maximum likelihood phylogenetic tree of vanA operons from 
2015-2017 Australian Group on Antimicrobial Australian Enterococcal Sepsis Outcome Program and 
international references. The outermost ring represents the operon type and the inner right represents sequence 




while most ST203 isolates harbored the 2A type. The international reference vanA operons 1618 
were associated with the ST80 and ST203 AESOP isolates.  1619 
5.5.2 vanB operon 1620 
The majority (81.2%) of the vanB operons did not harbor IS elements and were designated 1621 
vanB operon type 1B (Figure 5.3). For the remaining operons, the IS elements ISEfa11, ISL3 1622 
and IS110 were identified. In combination with the van genes present, five different vanB 1623 
operon types were identified. The most frequent vanB operon type harboring IS elements was 1624 
5B. Two vanB operon types, 3B and 4B, were only identified in one isolate each. The two most 1625 
frequent insertion sites for the IS element in the vanB operon was between vanSB and PvanY 1626 
and vanW and vanHB. The only exception was the 3B vanB operon type where the IS element 1627 
was identified downstream of the promoter, PvanY. No loss of van genes were detected in the 1628 
vanB operon. 1629 
  1630 
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Figure 5.3 The model vanB operon without insertion sequences followed by the five types of vanB 
operons identified in isolates from the 2015-2017 Australian Group on Antimicrobial Resistance 
Australian Enterococcal Sepsis Outcome Program. 
109 
 
The 1B vanB operon type was identified in 16 STs (Table 5.3). A range of vancomycin MICs 1632 
were identified across the vanB operon types, with 1B, 2B and 5B isolates exhibiting variable 1633 
vancomycin MICs. The vanB operon in isolates with a vancomycin susceptible phenotype did 1634 
not share similar SNP mutations and were not closely related phylogenetically (Figure 5.6-1635 
Supplementary). 1636 
Unlike the vanA operon, teicoplanin resistance is not typically conferred by the vanB operon. 1637 
The vast majority of isolates harbouing the vanB operon were teicoplanin susceptible. 1638 
However, several isolates harboring the 1B, 2B and 5B vanB operon type expressed teicoplanin 1639 
resistance. The vanB operon in isolates with a teicoplanin resistant phenotype did not share 1640 
similar SNP mutations. 1641 
  1642 
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Table 5.3 Summary of sequence types, vancomycin and teicoplanin minimum inhibitory concentrations identified in isolates harbouring the vanB operon 1643 
collected from the 2015-2017 Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Program. 1644 
vanB 








17, 18, 78, 80, 203, 233, 252, 479, 555, 796, 992, 1421, 
1423, 1429, 1543, 1557 
≤0.5, 1, 2, 8, ≥16 
≤1, 2, ≥16 
254 (81.2) 
2B 78, 80, 203, 555, 796 ≤0.5, 1, 2, 8, ≥16 ≤1, ≥16 13 (4.2) 
3B 78 2 ≤1 1(0.3) 
4B 78 ≥16 ≤1 1(0.3) 
5B 17, 78, 80, 117, 203, 341, 414, 1424 ≤0.5, ≥16 ≤1, 1, ≥16 44(14.1) 
 1645 
  1646 
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The majority of international reference vanB operons harbored the 1B vanB operon type which 1647 
does not contain IS elements. The two non-1B vanB operon types identified, harbored the IS 1648 
element, ISL3, in a unique configuration, vanRB – vanSB – ISL3 – vanYB – vanW – vanHB – 1649 
vanB – vanXB., which was not identified in the AESOP isolates. The vanB operons from ST78, 1650 
ST555 and ST796 AESOP isolates were not closely related to international reference operons. 1651 
The SNP inferred maximum-likelihood phylogenetic tree was rooted at a type 1B vanB operon 1652 
obtained from E. faecalis (Accession: AE016830) (Figure 5.4). Overall, low SNP differences 1653 
were observed amongst operons from the AESOP isolates. Similar vanB operon types and STs 1654 
were closely clustered on the phylogenetic tree. Operons typed as 1B were separated into two 1655 
clusters with international isolates located in the basal portion of the tree while 1B operons 1656 
from the AESOP isolates, belonging mainly to ST555 and ST796, were located in the most 1657 
distant branch of the tree. The 5B vanB operon type which was primarily harboured by the 1658 
AESOP isolates belonging to ST78 was flanked by the two 1B operon clusters.  1659 
  1660 
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Figure 5.4 Single nucleotide polymorphism inferred maximum likelihood phylogenetic tree of vanB 
operons from 2015-2017 Australian Group on Antimicrobial Australian Enterococcal Sepsis Outcome 
Program and international references. The outermost ring represents the operon type and the inner right 
represents sequence type as described in the figure legend. International isolates are labelled with 
accession numbers and country of origin. 
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5.5.3 vanAB  1662 
The six isolates harboring both vanA and vanB genotypes belonged to five different STs (two 1663 
ST80 isolates, and single isolates of ST203, ST233, ST252 and ST796). The vanA and vanB 1664 
operon type combination was unique for each ST with the two ST80 isolates harboring the 1665 
same combination. 1666 
  1667 
114 
 
5.6 DISCUSSION 1668 
In this study, we have identified multiple types of vanA and vanB operons in VREfm collected 1669 
from sepsis patients in Australia. The different van operon types were due to IS elements 1670 
inserted at specific intergenic regions between the regulatory, essential and accessory genes of 1671 
the van operon. Both vanA and vanB operons were generally associated with STs however 1672 
some exceptions were observed.  1673 
A larger diversity was observed for vanA operons compared to vanB operons. Additionally, 1674 
the loss of accessory genes without the loss of vancomycin resistance was observed in the vanA 1675 
operons. The ability to withstand mutations within the accessory gene region of the vanA 1676 
operon could perhaps be explained by the arrangement of the promoter binding site and van 1677 
genes within the operon. The promoter binding site for essential genes in the vanA operon is 1678 
located directly adjacent to and upstream of essential genes while, the promoter binding site 1679 
for the essential genes of the vanB operon is located upstream of the accessory genes. Mutations 1680 
in the accessory gene region of the vanA operon would therefore less likely affect expression 1681 
of essential genes compared to the vanB operon. Although the vanZ gene encoding teicoplanin 1682 
resistance (25) was absent from a number of vanA operon types, isolates were still able to 1683 
express teicoplanin resistance. 1684 
IS elements IS1380, IS1542, IS1251, IS1216E and ISEfa4 have previously been reported in 1685 
the E. faecium vanA operon (26, 27). The IS1542 element shares 81% sequence homology with 1686 
IS256 and contains an open reading frame capable of encoding a 390 amino acid sequence with 1687 
a predicted 87.2% identity with the transposase of IS256 (28). Additionally, IS1542 contains a 1688 
putative hybrid promoter binding site (29) possibly increasing the expression of genes 1689 
downstream. The additional promoter binding site provided by the insertion of IS1542 prior to 1690 
regulatory genes in the vanA operon may increase the expression of essential genes. Apart from 1691 
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having additional promoter sites, IS elements have also been implicated in the transposition of 1692 
antimicrobial resistance genes. IS1216E has been suggested to be involved in the dissemination 1693 
of cfr (30) and optrA (31). antimicrobial resistance genes. The cfr gene confers resistance to 1694 
five chemically unrelated antimicrobial classes, including phenicols, lincosamides, 1695 
oxazolidinones, pleuromutilins, and streptogramin A (32) while optrA encodes resistance to 1696 
oxazolidinones (linezolid and tedizolid) and phenicols (chloramphenicol and florfenicol) in 1697 
enterococci (33). However, cfr and optrA gene were not identified in the AESOP isolates. The 1698 
transposase, IS1380 family of IS elements, is widely identified in a diverse host range such as 1699 
Aerococcus, Carnobacterium and Escherichia coli but is not well characterized in E. faecium. 1700 
As is the case for ISEfa4 and IS1251, the function of the IS1380 element is not known. 1701 
The three IS elements identified in vanB operons, ISEfa11, ISL3 and IS110, have been 1702 
previously reported (34, 35). However, little is known about the role and function of the IS 1703 
elements.  1704 
The geographical distribution of IS elements identified within the vanA operon has been 1705 
reported (29).  For example IS1542 has been linked to the United Kingdom and Ireland (28) 1706 
while IS1251 and IS1476 have been associated with isolates from United States (36) and 1707 
Canada (37) respectively. In our study, the IS1541 from United Kingdom and Ireland and 1708 
IS1542 from United States were identified. However, for the AESOP isolates insufficient 1709 
epidemiological information was available on the geographical distribution of IS elements to 1710 
draw any conclusions. 1711 
Several international reference vanA operons were closely related to the AESOP vanA operons. 1712 
The vanA operon identified in the ST80 isolates were closely related to the reference operons 1713 
from United States (ST80), Hungary (unknown) and Denmark (ST80) whilst operons identified 1714 
in the ST203 isolates were closely related to the reference operons from South Korea (ST1421) 1715 
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and Denmark (ST203). However, in Australia the largest proportion of vanA operons, 1716 
identified in ST1421 and ST1424, were not related to the international references. For the vanB 1717 
operons, although international references and major Australian STs, 555 and 796, shared the 1718 
1B operon type, they were shown to be distinctly different by SNP phylogeny. International 1719 
vanB reference operons from the United States (ST117) and Sweden (ST117) were closely 1720 
related to operons from ST117 isolates in Australia. However, as with vanA, the largest 1721 
proportion of vanB operons were also was not identified in the international reference operons 1722 
suggesting an Australian lineage of van operons. 1723 
The SNP phylogeny of the van operon clustered according to STs which strongly suggests for 1724 
most isolates, the vertical transmission of the van operon has occurred. However, at the strain-1725 
level, multiple acquisitions of the van operon have occurred such as in ST203 and ST80, where 1726 
both vanA and vanB genotypes were identified. The typing of the van operon may provide 1727 
additional insights into the origin and transmission of vancomycin resistance. 1728 
In conclusion, our study of the van operons from the 2015-2017 AGAR AESOP isolates has 1729 
identified multiple IS elements at specific intergenic regions within the operon of both van 1730 
genotypes. A greater diversity of IS elements and operon types were observed for the vanA 1731 
operons. International reference operons used were not closely related to operons identified in 1732 
the major STs. Typing of the van operon may be useful in tracking the introduction of 1733 
vancomycin resistance into E. faecium strains particularly for STs with the same van genotype.  1734 
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5.8 SUPPLEMENTARY MATERIAL 1837 
Table 5.4 (Supplementary) List of international reference operons and associated accession numbers. 1838 
Van genotype Country Accession number ST Species 



























France CP025391 80 E. faecium 
Norway AM931300 Unknown E. faecium 
China CP025427 78 E. faecium 























France FJ767776 Unknown E. faecium 
Italy KT201628 209 E. faecium 
United 
Kingdom 
AF192329 Unknown E. faecalis 




  1840 
Figure 5.5 (Supplementary) A single nucleotide polymorphism based phylogenetic tree of isolates 
harbouring the vanA operon. From outermost ring: Teicoplanin minimum inhibitory concentrations and 
vancomycin of isolates harbouring the vanA operon. Missing values are indicative of reference isolates 
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Figure 5.6 (Supplementary) A single nucleotide polymorphism based phylogenetic tree of isolates 
harbouring the vanB operon. From outermost ring: Teicoplanin minimum inhibitory concentrations and 
vancomycin of isolates harbouring the vanA operon. Missing values are indicative of reference isolates 
with no available minimum inhibitory concentration data. 
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 CHAPTER 6 1842 
 1843 
General Discussion 1844 
  1845 
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6.1 PAPER 2 1846 
Molecular characterization and evolution of the first outbreak of vancomycin resistant  1847 
Enterococcus faecium in Western Australia. 1848 
 1849 
6.1.1 Findings 1850 
Using isolates collected at a single healthcare facility, a pilot study comparing the genetic 1851 
characteristics of outbreak and non-outbreak strains of vancomycin resistant Enterococcus 1852 
faecium (VREfm) was performed using whole genome sequencing and bioinformatics analysis.  1853 
The outbreak strain, identified as sequence type (ST)173, was collected during two consecutive 1854 
outbreaks in 2001 and 2004. Outbreak isolates formed three phylogenetic clades of increasing 1855 
isolate numbers indicating an increasingly successful strain. Additionally, the index isolate 1856 
collected was not identified as a founder suggesting isolates from the outbreak strain was 1857 
introduced to the facility prior to the index case reported.  1858 
A reduced number of virulence factors were identified in the outbreak strain, ST173, compared 1859 
to non-outbreak strains. Vancomycin resistance in the outbreak and non-outbreak isolates were 1860 
conferred by the vanB type operon despite prior vanA VREfm identified at the facility. 1861 
Aminoglycoside and erythromycin resistance was ubiquitous amongst outbreak and non-1862 
outbreak isolates. Although a larger genome size was observed in outbreak isolates compared 1863 
to non-outbreak isolates, no specific gain or loss of genes was identified. 1864 
6.1.2 Limitations and future directions 1865 
The intended function of the pilot study was to establish the methods used to characterize the 1866 
genome of outbreak and non-outbreak VREfm strains. However, due to the low prevalence of 1867 
non-outbreak VREfm at the facility, only a small number of non-outbreak isolates were 1868 
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available for comparison. More importantly, as a pilot study, investigations were limited to 1869 
only one outbreak strain. The further expansion of the study to include multiple outbreak strains 1870 
will offer a broader perspective on the genetic characteristics of outbreak VREfm. 1871 
6.1.3 Conclusion 1872 
Paper Two was a pilot study which identified the different genetic characteristics between 1873 
VREfm isolates from outbreak strain ST173 and non-outbreak strains occurring at a single 1874 
hospital facility. The work performed in this study leads to the next objective where multiple 1875 
outbreak strains were compared. 1876 
  1877 
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6.2 PAPER 3 1878 
The changing molecular epidemiology of vancomycin resistant Enterococcus faecium at 1879 
a teaching hospital in Western Australia: A fifteen-year retrospective study 1880 
6.2.1 Findings 1881 
Using isolates collected from 2001 to 2015 at Royal Perth Hospital as part of a surveillance 1882 
program monitoring VREfm colonization in patients admitted into high-risked units, eight 1883 
single-strain outbreaks were identified. Two outbreaks occurred in the first ten years while six 1884 
outbreaks occurred in the final five years. While the first two outbreaks, caused by ST17 was 1885 
only reported in WA, outbreak strains collected in the last five years of the study were reported 1886 
in other regions of Australia. A principle components analysis of total gene content in outbreak 1887 
strains showed distinct genetic differences between ST173 and the other outbreak strains. 1888 
Analogous genes conferring resistance to the similar antimicrobial classes were identified in 1889 
outbreak strains indicating the importance of aminoglycosides, tetracycline, trimethroprim, 1890 
lincosamides, macrolides and streptogramins resistance. Except for ST80 which harboured the 1891 
vanA genotype, vancomycin resistance in the outbreak strains were conferred by the vanB 1892 
genotype. Of note, the majority of ST78 isolates did not harbour the regulatory region of the 1893 
vanB operon resulting in vancomycin susceptibility. Although antimicrobial resistance gene 1894 
profiles for outbreak strains were unique, no increase in antimicrobial resistance was detected. 1895 
Genetic analysis of virulence factors identified a number of genes associated with adhesion and 1896 
survival but not toxin production or degradative enzymes. Except for ecbA  which was only 1897 
identified in ST203, the other virulence factors were identified in more than one outbreak 1898 
strain. Although the virulence gene profiles of outbreak strains were unique there was no 1899 
indication of additional virulence factor were identified over time.  1900 
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A SNP inferred phylogeny of outbreak isolates showed a strict clustering of isolates according 1901 
to ST which suggests the independent evolution of each outbreak strain. The unique virulence 1902 
profile and analogous resistance genes identified in outbreak strains further supports the 1903 
independent evolution of outbreak strains  1904 
6.2.2 Limitations and future directions 1905 
Due to the selection of only vancomycin resistant isolates, we could not determine the 1906 
importance of vancomycin resistance in outbreak strains of E. faecium. Additionally, as rectal-1907 
swabs were used to screen patients upon admission to high-risked units, the isolation of VREfm 1908 
only indicates colonization and therefore we cannot differentiate between commensal and 1909 
VREfm strains causing infections. More importantly, results from this study was observed from 1910 
only one hospital facility. Therefore, further investigations should include vancomycin 1911 
sensitive and resistant E. faecium isolates sampled from infected patients in multiple regions. 1912 
6.2.3 Conclusions 1913 
Paper Three identified differences in the virulome and resistome of VREfm outbreak strains 1914 
which were unrelated and evolved independently at RPH over a 15-year period. Although no 1915 
increase in virulence or antimicrobial resistance was observed over time, the importance of 1916 
resistance to several antimicrobial classes was observed.   1917 
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6.3 PAPER 4 1918 
A three-year whole genome sequencing perspective of  1919 
Enterococcus faecium sepsis in Australia 1920 
 1921 
6.3.1 Findings 1922 
Using isolates collected in the nationwide 2015-2017 Australian Group on Antimicrobial 1923 
Resistance (AGAR) Australian Enterococcal Sepsis Outcome Program (AESOP), a study was 1924 
performed to determine the genetic characteristics of E. faecium causing sepsis in Australia. 1925 
Two clonal complexes (CC), CC17 and CC94, harboured 118 sequence types, of which, only 1926 
eleven STs from CC17 were considered major having more than 20 isolates over the three-year 1927 
period. Phylogenetic analysis of all isolates identified three distinct clusters. The smallest 1928 
cluster harboured mostly CC94 isolates while the two larger clusters were dominant for isolates 1929 
harbouring the vanA and vanB operons respectively. A gradual increase in dominance of the 1930 
van operon was observed in each sub-branch of the two van dominant clusters suggesting a 1931 
strain-operon affinity. Additionally, when further divided into sub-clusters, the increase in 1932 
number of isolates and the 30-day all-cause mortality were linked to the increase in van operon 1933 
prevalence. Overall, the vanA dominant sub-cluster consisting of mostly ST1421 and ST1424 1934 
and the vanB dominant sub-cluster consisting of mostly ST555 and ST796, harboured the 1935 
majority of isolates.  1936 
Of the 61 virulence genes identified, only nine genes were present in more than five isolates. 1937 
The acm, bopD, bsh, clpP and sgrA virulence genes were ubiquitous amongst isolates from the 1938 
eleven major STs. Of the 26 antimicrobial resistance genes, only 20 were present in more than 1939 
five isolates. The msrC gene encoding erythromycin, macrolide and streptogramin B resistance 1940 
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was ubiquitous amongst isolates from the major STs. The proportion of major STs was different 1941 
in each geographical region with different dominant STs identified.  1942 
6.3.2 Limitations and future directions 1943 
Isolates for the AGAR AESOPs were limited to those collected from patients with blood stream 1944 
infections. While isolates were collected from every region within mainland Australia, isolates 1945 
were limited to only hospitals participating in the program. Moreover, frequent patient transfers 1946 
are known to occur across several regions. Therefore, regional distribution of E. faecium could 1947 
not be accurately determined. 1948 
The apparent link between the van operon and the success of an E. faecium strain identified in 1949 
paper 4 should be further investigated. Additionally, a risk assessment model using machine-1950 
learning can perhaps be developed to identify the outbreak potential of new emerging strains 1951 
using genetic markers that contribute to the success of a strain. 1952 
6.3.3 Conclusion 1953 
Paper 4 identified three clusters of E. faecium isolates and their genetic characteristics causing 1954 
sepsis in Australia. Additionally, a link was observed between the prevalence of the van operon 1955 
and the success of a strain. This leads to the next objective where the van operons in E. faecium 1956 
from Australia were investigated. 1957 
  1958 
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6.4 PAPER 5 1959 
Molecular characteristics of the van operon in vancomycin resistant Enterococcus 1960 
faecium blood stream infection isolates in Australia 1961 
6.4.1 Findings 1962 
Using 525 van operons from VREfm collected during the 2015-2017 AGAR AESOP, a study 1963 
was performed to determine the types and transmission of van operons within sepsis causing 1964 
VREfm isolates in Australia. Five insertion sequence (IS) elements were identified within the 1965 
vanA operon located on plasmids and three IS elements were identified within the vanB operon 1966 
located on the bacterial chromosomes. The IS elements identified in both van operons were 1967 
located at specific intergenic regions between the regulatory, functional and accessory van gene 1968 
clusters. Overall, eight vanA operon types and five vanB operon types were identified from the 1969 
combination of van genes and IS elements. While all vanA operons within the AESOP 1970 
collection harboured IS elements, the majority of vanB operons did not harbour IS elements.  1971 
SNP inferred phylogenetics showed vanA and vanB operon types were generally clustered by 1972 
isolate ST indicating the vertical transmission of the van operon for most isolates. However, at 1973 
the strain level, the presence of vanA and vanB operons within isolates of the same ST indicate 1974 
the multiple acquisitions of the van operon has occurred.  1975 
Phylogenetically, the majority of vanA and vanB operons from AESOP isolates belonging to 1976 
dominant STs, ST1421 and ST1424 for vanA operons and ST555 and ST796 for vanB operons, 1977 
were distantly related to international reference van operons suggesting an Australian lineage 1978 
of vanA and vanB operons in the dominant STs. 1979 
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6.4.2 Limitations and future directions 1980 
The short-read length obtained from sequencing was not able to correctly resolve repeat regions 1981 
identified in IS elements. The majority of assembled van operons were fragmented and had to 1982 
be assembled manually. Where possible, long-read reference van operons from genome 1983 
databases were used as scaffolds in assembly. However, several van operon types were novel 1984 
and reference scaffold van operons were created in silico. As such, novel van operons could 1985 
not be validated. Additionally, only few international long-read van operon references were 1986 
available for comparison.  1987 
Future work should include recent international VREfm to provide a global perspective on the 1988 
transmission of the vanA and vanB operon. Additionally, long-read sequencing may be used 1989 
to validate novel van operons identified in this study. 1990 
6.4.3 Conclusion 1991 
Paper 5 identified multiple IS elements within the vanA and vanB operons. The combination 1992 
of the IS elements and van genes resulted in eight vanA operon types and five vanB operon 1993 
types which were typically vertically transmitted. The presence of vanA and vanB operons 1994 
within an ST suggests the multiple acquisitions of vancomycin resistance occurred within the 1995 
same strain. 1996 
As the vanA and vanB operons are located on mobile genetic elements, using data from this 1997 
study, we are now able to track the transmission and the emergence of new vanA and vanB 1998 
operons in Australia. 1999 
  2000 
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6.5 CONCLUSION 2001 
Enterococcus faecium is a ubiquitous member of the mammalian gut microbiome that has 2002 
become a major nosocomial pathogen. Identified as members of clonal complex (CC)17, 2003 
hospital-adapted E. faecium typically cause infections in immune compromised hosts that may 2004 
be unresponsive to antimicrobial therapy. In the last three decades, a global pandemic caused 2005 
by CC17 E. faecium resistant to vancomycin, a key antimicrobial used in the treatment of 2006 
severe Gram-positive infections has occurred. With the high prevalence of VREfm, the 2007 
transmission of van operons conferring vancomycin resistance between bacteria threatens the 2008 
prolonged clinical efficacy of vancomycin.  2009 
In chapters 2 and 3, we have shown that outbreak strains of VREfm at a single-hospital facility 2010 
were not closely related suggesting they did not evolve from strains present at the facility and 2011 
were most likely introduced. Although no increase in antimicrobial resistance was observed 2012 
within outbreak strains, the presence of analogous genes conferring similar antimicrobial 2013 
resistances amongst outbreak strains suggests the importance of antimicrobial resistance 2014 
towards strain survival. As the majority of VREfm isolated were from colonized patients, the 2015 
lack of increasing virulence factors amongst outbreak strains was not unexpected. The constant 2016 
rise and fall of outbreak STs at RPH suggest dominant STs at single-hospital facilities were 2017 
ephemeral and constantly changing. 2018 
In chapters 4 and 5, we have shown that the high prevalence of VREfm causing blood stream 2019 
infections in Australia was caused by two phylogenetic clusters of CC17 E. faecium dominant 2020 
for the the vanA and vanB operons respectively. In both clusters, an increase in the prevalence 2021 
of the van operon was associated with an increased 30-day all-cause mortality and number of 2022 
isolates collected. STs of isolates identified previously in chapter 3 were identified in the two 2023 
van operon dominant clusters suggesting similar E. faecium strains were responsible for 2024 
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colonization and infection in patients. Additional IS elements identified within van operons 2025 
were used to type both vanA and vanB operons. A strain-van operon affinity was observed 2026 
with the vanA operon dominant in ST1421 and ST1424 while the vanB operon was dominant 2027 
in ST555 and ST796. The van operon types identified in ST1421, ST1424, ST555 and ST796 2028 
were not closely related to international reference operons suggesting local lineages of vanA 2029 
and vanB operons.  2030 
Geographically, although each region in Australia was observed to have a dominant E. faecium 2031 
strain, we have previously shown dominant strains rapidly change due to the rise and fall of 2032 
outbreak strains. Therefore, the strain distribution described in chapter 4 is only a snapshot and 2033 
may be different in the future. 2034 
The studies included in this thesis show the on-going evolutionary changes of E. faecium and 2035 
in particular VREfm in Australia. The movement of E. faecium strains and van operons are 2036 
central to the changing epidemiology of VREfm. Ultimately it is the external selection pressure 2037 
exerted on CC17 E. faecium which shapes the genetic and phenotypic characteristics observed.  2038 
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